stella
← For Researchers/Lp(a)/Research Sites

Lp(a) Research Sites

Sites currently running trials · ranked by activity

EndometriosisLong COVIDALSPTSDSickle Cell DiseaseLupusProstate CancerMenopauseLp(a)

2464 sites · 3640 trials · June 2026

Recruiting
Opening soon
Active · not recruiting
1

National Heart Institute

Beverly Hills · California · United States

8 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
2

Jacksonville Center for Clinical Research

Jacksonville · Florida · United States

7 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
3

Virginia Heart

Falls Church · Virginia · United States

7 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
4

Intermountain Medical Center

Murray · Utah · United States

6 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
5

Anderson Medical Research

Ft. Washington · Maryland · United States

6 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
6

Novartis Investigative Site

Beijing · China

6 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
7

Heart Center Research Llc

Huntsville · Alabama · United States

5 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
8

Excel Medical Clinical Trials LLC

Boca Raton · Florida · United States

5 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
9

Henry Ford Hospital

Detroit · Michigan · United States

5 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
10

Novartis Investigative Site

Wenzhou · Zhejiang · China

5 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
11

Novartis Investigative Site

Berlin · Germany

5 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
12

Novartis Investigative Site

Münster · Germany

5 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
13

Eclipse Clinical Research

Tucson · Arizona · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
14

Valley Clinical Trials

Northridge · California · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
15

Peace River Cardiovascular Center

Port Charlotte · Florida · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
16

Johns Hopkins University

Columbia · Maryland · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
17

AA Medical Research Center

Flint · Michigan · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
18

University Of Minnesota

Minneapolis · Minnesota · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
19

Overlook Medical Center

Summit · New Jersey · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
20

Wake Forest University Baptist Medical Center

Winston-Salem · North Carolina · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
21

Ohio State University

Columbus · Ohio · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
22

Northwest Houston Clinical Research PLLC

Tomball · Texas · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
23

Carient Heart and Vascular

Manassas · Virginia · United States

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
24

Novartis Investigative Site

Shenyang · Liaoning · China

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
25

Novartis Investigative Site

Xian · Shanxi · China

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
26

Novartis Investigative Site

Chengdu · Sichuan · China

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
27

Novartis Investigative Site

Shanghai · China

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
28

Novartis Investigative Site

Paris · France

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
29

Novartis Investigative Site

Mannheim · Germany

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
30

Novartis Investigative Site

Frankfurt am Main · Hesse · Germany

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
31

Novartis Investigative Site

Essen · Germany

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
32

Novartis Investigative Site

Dresden · Germany

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
33

Novartis Investigative Site

Leipzig · Saxony · Germany

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
34

Novartis Investigative Site

Potsdam · Germany

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
35

Novartis Investigative Site

Ancona · AN · Italy

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
36

Novartis Investigative Site

Milan · MI · Italy

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
37

Novartis Investigative Site

Córdoba · Spain

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
38

Novartis Investigative Site

London · United Kingdom

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
39

Novartis Investigative Site

Manchester · United Kingdom

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
40

Novartis Investigative Site

Tyne and Wear · United Kingdom

4 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
41

Vector Clinical Trials

Las Vegas · Nevada · United States

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
42

Eastside Research Associates

Redmond · Washington · United States

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
43

Nightingale Research

Adelaide · Australia

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
44

Advara HeartCare Joondalup

Joondalup · Australia

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
45

Semmelweis University

Budapest · Hungary

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
46

CHUAC-Complejo Hospitalario Universitario A Coruña

A Coruña · Spain

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
47

Parc de Salut Mar - Hospital del Mar

Barcelona · Spain

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
48

Hospital Universitario Reina Sofia

Córdoba · Spain

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
49

Hospital Universitario Ramón y Cajal

Madrid · Spain

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
50

Hospital Universitario Virgen Del Rocio

Seville · Spain

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
51

Hospital General Universitario de Valencia

Valencia · Spain

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
52

Bristol Royal Infirmary

Bristol · United Kingdom

3 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
53

Mobile Heart Specialists

Mobile · Alabama · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
54

Mercy Gilbert Medical Center

Gilbert · Arizona · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
55

Clinical Research Inst of Arizona

Sun City West · Arizona · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
56

Cardiology and Medicine Clinic PA

Little Rock · Arkansas · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
57

Cardiovascular Res Found

Beverly Hills · California · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
58

Stanford University Medical Center

Palo Alto · California · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
59

Manshadi Heart Institute

Stockton · California · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
60

Interv Cardiology Med Grp

West Hills · California · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
61

Bridgeport Hospital

Bridgeport · Connecticut · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
62

Chase Medical Research LLC

Waterbury · Connecticut · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
63

Advanced Research for Health Improvement LLC

Naples · Florida · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2WITHDRAWNNCT05646381 ↗
64

Progressive Medical Research

Port Orange · Florida · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
65

Cardiology Partners Clinical Research Institute

Wellington · Florida · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
66

Cardiovascular Associates Research

Covington · Louisiana · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
67

Omega Clinical Research

Metairie · Louisiana · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
68

Brigham and Womens Hosp Harvard Med School

Boston · Massachusetts · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
69

Minneapolis Heart Institute

Minneapolis · Minnesota · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2WITHDRAWNNCT05646381 ↗
70

StudyMetrix Research

City of Saint Peters · Missouri · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
71

Icahn School of Med at Mt Sinai

New York · New York · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
72

Lenox Hill Hospital

New York · New York · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
73

Northwell Health Physician Peconic

Riverhead · New York · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
74

Medication Management LLC

Greensboro · North Carolina · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
75

Lindner Ctr At The Christ Hosp

Cincinnati · Ohio · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
76

Perelman School of Medicine

Philadelphia · Pennsylvania · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
77

Cardiology Consultants of Philadelphia

Yardley · Pennsylvania · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
78

Monument Health Clinical Research

Rapid City · South Dakota · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
79

Apex Cardiology Research Associates of Jackson

Jackson · Tennessee · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
80

UT Southwestern Medical Center

Dallas · Texas · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
81

Baylor College Of Medicine

Houston · Texas · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
82

Progressive Clinical Research

Bountiful · Utah · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
83

Dominion Medical Associates

Richmond · Virginia · United States

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
84

Novartis Investigative Site

Innsbruck · Austria

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
85

Novartis Investigative Site

Linz · Austria

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2WITHDRAWNNCT05646381 ↗
86

Novartis Investigative Site

Vienna · Austria

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
87

Novartis Investigative Site

Genk · Limburg · Belgium

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
88

Novartis Investigative Site

Aalst · Oost Vlaanderen · Belgium

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
89

Novartis Investigative Site

Kortrijk · West-Vlaanderen · Belgium

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
90

Novartis Investigative Site

Montreal · Quebec · Canada

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
91

Novartis Investigative Site

Québec · Quebec · Canada

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
92

Novartis Investigative Site

Lanzhou · Gansu · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
93

Novartis Investigative Site

Guangzhou · Guangdong · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
94

Novartis Investigative Site

Harbin · Heilongjiang · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
95

Novartis Investigative Site

Baotou · Inner Mongolia · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
96

Novartis Investigative Site

Changchun · Jilin · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
97

Novartis Investigative Site

Dalian · Liaoning · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
98

Novartis Investigative Site

Ürümqi · Xinjiang · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
99

Novartis Investigative Site

Hangzhou · Zhejiang · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
100

Novartis Investigative Site

Tianjin · China

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
101

Novartis Investigative Site

Prague · Czechia

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
102

Novartis Investigative Site

Esbjerg · Denmark

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
103

Novartis Investigative Site

Roskilde · Denmark

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
104

Novartis Investigative Site

Viborg · Denmark

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
105

Novartis Investigative Site

Grenoble · France

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
106

Novartis Investigative Site

Toulouse · France

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
107

Novartis Investigative Site

Munich · Bavaria · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
108

Novartis Investigative Site

Chemnitz · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
109

Novartis Investigative Site

Bad Krozingen · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
110

Novartis Investigative Site

Bad Oeynhausen · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
111

Novartis Investigative Site

Bielefeld · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
112

Novartis Investigative Site

Dortmund · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
113

Novartis Investigative Site

Gelnhausen · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
114

Novartis Investigative Site

Hamburg · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
115

Novartis Investigative Site

Lüneburg · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2WITHDRAWNNCT05646381 ↗
116

Novartis Investigative Site

Magdeburg · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
117

Novartis Investigative Site

München · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
118

Novartis Investigative Site

Rüdersdorf · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2WITHDRAWNNCT07235046 ↗
119

Novartis Investigative Site

Warendorf · Germany

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
120

Novartis Investigative Site

Hong Kong · Hong Kong

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
121

Novartis Investigative Site

Beersheba · Israel

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
122

Novartis Investigative Site

Haifa · Israel

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
123

Novartis Investigative Site

Jerusalem · Israel

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
124

Novartis Investigative Site

Petah Tikva · Israel

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
125

Novartis Investigative Site

Ramat Gan · Israel

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
126

Novartis Investigative Site

Bergamo · BG · Italy

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
127

Novartis Investigative Site

Bologna · BO · Italy

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2WITHDRAWNNCT05646381 ↗
128

Novartis Investigative Site

Brescia · BS · Italy

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
129

Novartis Investigative Site

Cona · FE · Italy

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
130

Novartis Investigative Site

Pozzilli · IS · Italy

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
131

Novartis Investigative Site

Rozzano · MI · Italy

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
132

Novartis Investigative Site

Perugia · PG · Italy

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
133

Novartis Investigative Site

Salerno · SA · Italy

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
134

Novartis Investigative Site

Matsudo · Chiba · Japan

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
135

Novartis Investigative Site

Takamatsu · Kagawa-ken · Japan

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
136

Novartis Investigative Site

Miyhazaki · Miyazaki · Japan

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
137

Novartis Investigative Site

Amsterdam · North Holland · Netherlands

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
138

Novartis Investigative Site

The Hague · South Holland · Netherlands

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
139

Novartis Investigative Site

Coimbra · Portugal

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
140

Novartis Investigative Site

Santiago Compostela · A Coruna · Spain

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
141

Novartis Investigative Site

Cáceres · Extremadura · Spain

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
142

Novartis Investigative Site

A Coruña · Spain

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
143

Novartis Investigative Site

Barcelona · Spain

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
144

Novartis Investigative Site

Huelva · Spain

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
145

Novartis Investigative Site

Madrid · Spain

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
146

Novartis Investigative Site

Valencia · Spain

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
147

Novartis Investigative Site

Basel · Switzerland

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
148

Novartis Investigative Site

Geneva · Switzerland

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
149

Novartis Investigative Site

Lausanne · Switzerland

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
150

Novartis Investigative Site

Zurich · Switzerland

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2WITHDRAWNNCT05646381 ↗
151

Novartis Investigative Site

Kaohsiung City · Taiwan

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
152

Novartis Investigative Site

Tainan · Taiwan

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
153

Novartis Investigative Site

Taipei · Taiwan

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
154

Novartis Investigative Site

Portadown · Nothern Ireland · United Kingdom

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
155

Novartis Investigative Site

Chichester · West Sussex · United Kingdom

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
156

Novartis Investigative Site

Edinburgh · United Kingdom

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
157

Novartis Investigative Site

Londonderry · United Kingdom

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
158

Novartis Investigative Site

Middlesbrough · United Kingdom

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
159

Novartis Investigative Site

Norwich · United Kingdom

3 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
160

Excel Medical Clinical Trials

Boca Raton · Florida · United States

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
161

Ocala Cardiovascular Research

Ocala · Florida · United States

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
162

North Georgia Clinical Research

Woodstock · Georgia · United States

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
163

Ascension Saint Agnes Heart Care

Baltimore · Maryland · United States

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
164

Walker Family Care

Little River · South Carolina · United States

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
165

Fusion Clinical Research

Norwood · South Australia · Australia

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
166

Victorian Heart Hospital

Clayton · Victoria · Australia

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
167

Victoria Heart Institute Foundation

Victoria · British Columbia · Canada

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
168

Premier Clinical Trial Network

Hamilton · Ontario · Canada

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
169

North York Diagnostic and Cardiac Centre

North York · Ontario · Canada

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
170

Ecogene-21

Chicoutimi · Quebec · Canada

3 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
171

Inpatient Research Clinical LLC

Miami Lakes · Florida · United States

3 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
172

Novartis Investigative Site

Jining · Shandong · China

3 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
173

UCSD - Altman Clinical and Translational Research Institute (ACTRI)

La Jolla · California · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
174

Valley Clinical Trials, Inc.

Northridge · California · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
175

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance · California · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
176

Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care

Fort Lauderdale · Florida · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
177

Inpatient Research Clinic

Miami Lakes · Florida · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
178

CARE Institute - High Desert

Meridian · Idaho · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
179

Massachusetts General Hospital

Boston · Massachusetts · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
180

Heart and Vascular Research at WellSpan Health

York · Pennsylvania · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
181

Carilion Clinic

Roanoke · Virginia · United States

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
182

Core Research Group

Brisbane · Australia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
183

Advara HeartCare - Burwood

Burwood · Australia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
184

Advara HeartCare Leabrook

Leabrook · Australia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
185

AIM Research

Merewether · Australia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
186

Advara HeartCare - Mulgrave

Mulgrave · Australia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
187

USC Clinical Trials Brisbane (South Bank)

South Brisbane · Australia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
188

Clinitrials

West Perth · Australia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
189

Fakultni Nemocnice u sv. Anny v Brne

Brno · Czechia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
190

EFERTUS healthcare s.r.o.

Brno · Czechia

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
191

Óbudai Egészségügyi Centrum

Budapest · Hungary

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
192

Ziekenhuis St. Jansdal

Harderwijk · Netherlands

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
193

Radboudumc

Nijmegen · Netherlands

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
194

VieCuri Medisch Centrum, locatie Venlo

Venlo · Netherlands

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
195

Hospital Insular de Gran Canaria

Las Palmas de Gran Canaria · Spain

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
196

Hospital Clinico San Carlos

Madrid · Spain

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
197

Hospital Universitario Virgen Macarena

Seville · Spain

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
198

Cheadle Community Hospital

Cheadle · United Kingdom

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
199

Lister Hospital

Stevenage · United Kingdom

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
200

FutureMeds Teesside - Middlefield Centre

Stockton-on-Tees · United Kingdom

2 trials
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
201

Research Site

Glendale · California · United States

2 trials
Laroprovstat and AZD4954 interaction study measures how these drugs affect each other in healthy adults.
AstraZenecaPh 1RecruitingNCT07513571 ↗
AZD4954 safety and effectiveness study in healthy adults and those with high cholesterol or lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
202

SEC Clinical Research LLC

Andalusia · Alabama · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
203

Flourish Clinical Resrch Covin

Covina · California · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
204

University of Calif Irvine Med Cntr

Irvine · California · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
205

Keck Medical Center USC

Los Angeles · California · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
206

University of California San Diego

San Diego · California · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
207

UCSF

San Francisco · California · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
208

Helping Hands Medical Associates INC

Santa Ana · California · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
209

Univ Of Color Anschutz Med Center

Aurora · Colorado · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
210

Hartford Hospital

Hartford · Connecticut · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
211

Bay Area Cardiology Assoc

Brandon · Florida · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
212

Westside Center for Clinical Research

Jacksonville · Florida · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
213

East Coast Inst for Research LLC

Saint Augustine · Florida · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
214

Piedmont Heart Institute

Atlanta · Georgia · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
215

Emory University

Atlanta · Georgia · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
216

Cardiovascular Consultants of S GA

Thomasville · Georgia · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
217

Rush University Medical Center

Chicago · Illinois · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
218

Advocate Lutheran General Childrens Hospital

Park Ridge · Illinois · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
219

Krannert Institute of Cardiology

Indianapolis · Indiana · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
220

Uni Of Iowa Hospitals And Clinics

Iowa City · Iowa · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
221

University of Kansas Hospital

Kansas City · Kansas · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
222

Cotton O Neil Clinical Res Center

Topeka · Kansas · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
223

Louisiana Heart Center Research

Covington · Louisiana · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
224

CV Institute of the South

Houma · Louisiana · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
225

Horizon Research Grp

Lafayette · Louisiana · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
226

CV Ins of the South

Opelousas · Louisiana · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
227

Grace Research Llc

Shreveport · Louisiana · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
228

Louisiana Heart Center Research

Slidell · Louisiana · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
229

Southern Clinical Research

Zachary · Louisiana · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
230

Maine Health Cardiology

Scarborough · Maine · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
231

Sinai Ct for Throm Res and Drug Dev

Baltimore · Maryland · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
232

Johns Hopkins Univ School of Med

Baltimore · Maryland · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
233

Adventist HealthCare Shady Grove Medical Center

Rockville · Maryland · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
234

MGH

Boston · Massachusetts · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
235

Wayne State University

Detroit · Michigan · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
236

Western Michigan University

Kalamazoo · Michigan · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
237

McLaren Ctr Research Innovation

Petoskey · Michigan · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
238

Central Michigan University

Saginaw · Michigan · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
239

Metro Health Univ of MI Health

Wyoming · Michigan · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
240

Saint Johns Hospital

Maplewood · Minnesota · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
241

Belzoni Clinical Research

Belzoni · Mississippi · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
242

Stern Cardiovascular Foundation Inc

Southaven · Mississippi · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
243

Washington Univ School Of Medicine

St Louis · Missouri · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
244

Quality Clinical Research

Omaha · Nebraska · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
245

Dartmouth Hitchcock Medical Center

Lebanon · New Hampshire · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
246

The Valley Hospital

Ridgewood · New Jersey · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
247

Albany Medical College

Albany · New York · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
248

Northwell Health

Manhasset · New York · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
249

Weill Cornell Medical Center

New York · New York · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
250

Strong Memorial Hospital

Rochester · New York · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
251

Novant Health Heart Vas Inst

Charlotte · North Carolina · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
252

Accellacare US Inc

Raleigh · North Carolina · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
253

Aultman Hospital

Canton · Ohio · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
254

Cleveland Clinic Foundation

Cleveland · Ohio · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
255

Rama Research LLC

Marion · Ohio · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
256

Lancaster General Health

Lancaster · Pennsylvania · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
257

The Stern Cardiovascular Foundation

Germantown · Tennessee · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
258

Vanderbilt Univ Medi Cen

Nashville · Tennessee · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
259

Cardiovascular Res of Knoxville LLC

Powell · Tennessee · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
260

Soltero Cardiovascular Research Center

Dallas · Texas · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
261

North Texas Endocrine Center

Dallas · Texas · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
262

SW Family Medicine Associates

Dallas · Texas · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
263

Grace Research

Marshall · Texas · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
264

The University of Utah

Salt Lake City · Utah · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
265

Inova Fairfax Hospital

Falls Church · Virginia · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
266

York Clinical Research

Norfolk · Virginia · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
267

Harborview Medical Center

Seattle · Washington · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
268

Swedish Medical Center-Cardiovascular Research

Seattle · Washington · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
269

Univ of Washington Medical Center

Seattle · Washington · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
270

West Virginia University Hospital

Morgantown · West Virginia · United States

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
271

Novartis Investigative Site

CABA · Buenos Aires · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
272

Novartis Investigative Site

Mar del Plata · Buenos Aires · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
273

Novartis Investigative Site

Ramos Mejía · Buenos Aires · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
274

Novartis Investigative Site

Córdoba · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
275

Novartis Investigative Site

San Miguel de Tucumán · San Miguel de Tucuman · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
276

Novartis Investigative Site

Rosario · Santa Fe Province · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
277

Novartis Investigative Site

Santa Fe · Santa Fe Province · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
278

Novartis Investigative Site

Capital Federal · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
279

Novartis Investigative Site

Corrientes · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
280

Novartis Investigative Site

San Luis · Argentina

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
281

Novartis Investigative Site

Camperdown · New South Wales · Australia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
282

Novartis Investigative Site

Chemside · Queensland · Australia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
283

Novartis Investigative Site

Woolloongabba · Queensland · Australia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
284

Novartis Investigative Site

Clayton · Victoria · Australia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
285

Novartis Investigative Site

Perth · Western Australia · Australia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
286

Novartis Investigative Site

Liverpool · Australia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
287

Novartis Investigative Site

Graz · Austria

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
288

Novartis Investigative Site

Salzburg · Austria

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
289

Novartis Investigative Site

Brussels · Brussels Capital · Belgium

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
290

Novartis Investigative Site

Bruges · Belgium

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
291

Novartis Investigative Site

Dendermonde · Belgium

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
292

Novartis Investigative Site

Huy · Belgium

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
293

Novartis Investigative Site

Mechelen · Belgium

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
294

Novartis Investigative Site

Vitória · Espírito Santo · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
295

Novartis Investigative Site

Salvador · Estado de Bahia · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
296

Novartis Investigative Site

Goiânia · Goiás · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
297

Novartis Investigative Site

Belo Horizonte · Minas Gerais · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
298

Novartis Investigative Site

Juiz de Fora · Minas Gerais · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
299

Novartis Investigative Site

Uberlândia · Minas Gerais · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
300

Novartis Investigative Site

Curitiba · Paraná · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
301

Novartis Investigative Site

Canoas · Rio Grande do Sul · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
302

Novartis Investigative Site

Porto Alegre · Rio Grande do Sul · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
303

Novartis Investigative Site

Blumenau · Santa Catarina · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
304

Novartis Investigative Site

Aracaju · Sergipe · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
305

Novartis Investigative Site

Campinas · São Paulo · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
306

Novartis Investigative Site

Ribeirão Preto · São Paulo · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
307

Novartis Investigative Site

Santo André · São Paulo · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
308

Novartis Investigative Site

Sao Jose Rio Preto · São Paulo · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
309

Novartis Investigative Site

São Paulo · São Paulo · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
310

Novartis Investigative Site

Rio de Janeiro · Brazil

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
311

Novartis Investigative Site

Burgas · Bulgaria

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
312

Novartis Investigative Site

Pernik · Bulgaria

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
313

Novartis Investigative Site

Pleven · Bulgaria

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
314

Novartis Investigative Site

Plovdiv · Bulgaria

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
315

Novartis Investigative Site

Rousse · Bulgaria

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
316

Novartis Investigative Site

Sofia · Bulgaria

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
317

Novartis Investigative Site

Vancouver · British Columbia · Canada

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
318

Novartis Investigative Site

Oakville · Ontario · Canada

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
319

Novartis Investigative Site

Toronto · Ontario · Canada

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
320

Novartis Investigative Site

Lévis · Quebec · Canada

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
321

Novartis Investigative Site

Foshan · Guangdong · China

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
322

Novartis Investigative Site

Changsha · Hunan · China

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
323

Novartis Investigative Site

Nanjing · Jiangsu · China

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
324

Novartis Investigative Site

Suzhou · Jiangsu · China

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
325

Novartis Investigative Site

Xuzhou · Jiangsu · China

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
326

Novartis Investigative Site

Jinan · Shandong · China

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
327

Novartis Investigative Site

Xiamen · China

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
328

Novartis Investigative Site

Medellín · Colombia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
329

Novartis Investigative Site

Barranquilla · Colombia · Colombia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
330

Novartis Investigative Site

Bucaramanga · Santander Department · Colombia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
331

Novartis Investigative Site

Cali · Valle del Cauca Department · Colombia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
332

Novartis Investigative Site

Bogotá · Colombia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
333

Novartis Investigative Site

San Gil · Colombia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
334

Novartis Investigative Site

Chlumec nad Cidlinou · Chlumec Nad Cidlinou · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
335

Novartis Investigative Site

Kroměříž · Czech Republic · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
336

Novartis Investigative Site

Louny · Czech Republic · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
337

Novartis Investigative Site

Ostrava · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
338

Novartis Investigative Site

Ústí nad Labem · Czech Republic · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
339

Novartis Investigative Site

Brandýs nad Labem · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
340

Novartis Investigative Site

Brno · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
341

Novartis Investigative Site

Broumov · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
342

Novartis Investigative Site

CZE · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
343

Novartis Investigative Site

Český Krumlov · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
344

Novartis Investigative Site

Hlučín · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
345

Novartis Investigative Site

Hodonín · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
346

Novartis Investigative Site

Jihlava · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
347

Novartis Investigative Site

Kolín · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
348

Novartis Investigative Site

Liberec · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
349

Novartis Investigative Site

Mariánské Lázně · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
350

Novartis Investigative Site

Mělník · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
351

Novartis Investigative Site

Most · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
352

Novartis Investigative Site

Olomouc · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
353

Novartis Investigative Site

Pardubice · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
354

Novartis Investigative Site

Polička · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
355

Novartis Investigative Site

Přerov · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3WITHDRAWNNCT07517263 ↗
356

Novartis Investigative Site

Slaný · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
357

Novartis Investigative Site

Trutnov · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
358

Novartis Investigative Site

Třebíč · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
359

Novartis Investigative Site

Uherské Hradiště · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
360

Novartis Investigative Site

Valašské Meziříčí · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
361

Novartis Investigative Site

Zlín · Czechia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
362

Novartis Investigative Site

Aarhus N · Denmark

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
363

Novartis Investigative Site

Copenhagen · Denmark

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
364

Novartis Investigative Site

Gistrup · Denmark

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
365

Novartis Investigative Site

Herlev · Denmark

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
366

Novartis Investigative Site

Bron · France

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
367

Novartis Investigative Site

Chambray-lès-Tours · France

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
368

Novartis Investigative Site

Compiègne · France

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
369

Novartis Investigative Site

Le Coudray · France

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
370

Novartis Investigative Site

Lille · France

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
371

Novartis Investigative Site

Nantes · France

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
372

Novartis Investigative Site

Valenciennes · France

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
373

Novartis Investigative Site

Muehldorf Am Inn · Bavaria · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
374

Novartis Investigative Site

Weiden in Der Oberpfalz · Bavaria · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
375

Novartis Investigative Site

Hanover · Lower Saxony · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
376

Novartis Investigative Site

Cologne · North Rhine-Westphalia · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
377

Novartis Investigative Site

Löhne · North Rhine-Westphalia · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
378

Novartis Investigative Site

Saint Ingbert · Saarland · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
379

Novartis Investigative Site

Wittenberg · Saxony-Anhalt · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
380

Novartis Investigative Site

Jena · Thuringia · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
381

Novartis Investigative Site

Aachen · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
382

Novartis Investigative Site

Bad Homburg · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
383

Novartis Investigative Site

Bamberg · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
384

Novartis Investigative Site

Dessau · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
385

Novartis Investigative Site

Kassel · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
386

Novartis Investigative Site

Meissen · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
387

Novartis Investigative Site

Ulm · Germany

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
388

Novartis Investigative Site

Athens · Greece

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
389

Novartis Investigative Site

Ioannina · Greece

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
390

Novartis Investigative Site

Larissa · Greece

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
391

Novartis Investigative Site

Thessaloniki · Greece

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
392

Novartis Investigative Site

Debrecen · Hajdu Bihar Megye · Hungary

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
393

Novartis Investigative Site

Baja · Hungary

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
394

Novartis Investigative Site

Budapest · Hungary

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
395

Novartis Investigative Site

Szeged · Hungary

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
396

Novartis Investigative Site

Guntur · Andhra Pradesh · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
397

Novartis Investigative Site

Hyderabad · Telangana · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
398

Novartis Investigative Site

Ahmedabad · Gujarat · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
399

Novartis Investigative Site

Vadodara · Gujarat · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
400

Novartis Investigative Site

Belagavi · Karnataka · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
401

Novartis Investigative Site

Mangalore · Karnataka · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
402

Novartis Investigative Site

Manipal · Karnataka · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
403

Novartis Investigative Site

Mysore · Karnataka · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
404

Novartis Investigative Site

Kochi · Kerala · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
405

Novartis Investigative Site

Nagpur · Maharashtra · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
406

Novartis Investigative Site

Nashik · Maharashtra · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
407

Novartis Investigative Site

Pune · Maharashtra · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
408

Novartis Investigative Site

New Delhi · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
409

Novartis Investigative Site

Bikaner · Rajasthan · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
410

Novartis Investigative Site

Chennai · Tamil Nadu · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
411

Novartis Investigative Site

Coimbatore · Tamil Nadu · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
412

Novartis Investigative Site

Secunderabad · Telangana · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
413

Novartis Investigative Site

Ghaziabad · Uttar Pradesh · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
414

Novartis Investigative Site

Lucknow · Uttar Pradesh · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
415

Novartis Investigative Site

Dehradun · Uttarakhand · India

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
416

Novartis Investigative Site

Holon · Israel

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
417

Novartis Investigative Site

Florence · FI · Italy

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
418

Novartis Investigative Site

Palermo · PA · Italy

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
419

Novartis Investigative Site

Pisa · PI · Italy

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
420

Novartis Investigative Site

Roma · RM · Italy

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
421

Novartis Investigative Site

Varese · VA · Italy

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
422

Novartis Investigative Site

Naples · Italy

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
423

Novartis Investigative Site

Seto · Aichi-ken · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
424

Novartis Investigative Site

Hirosaki · Aomori · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
425

Novartis Investigative Site

Asahi · Chiba · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
426

Novartis Investigative Site

Funabashi · Chiba · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
427

Novartis Investigative Site

Kitakyushu · Fukuoka · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
428

Novartis Investigative Site

Ōgaki · Gifu · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
429

Novartis Investigative Site

Kure · Hiroshima · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
430

Novartis Investigative Site

Tsuchiura · Ibaraki · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
431

Novartis Investigative Site

Komatsu · Ishikawa-ken · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
432

Novartis Investigative Site

Kawasaki · Kanagawa · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
433

Novartis Investigative Site

Sagamihara · Kanagawa · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
434

Novartis Investigative Site

Yokohama · Kanagawa · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
435

Novartis Investigative Site

Sendai · Miyagi · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
436

Novartis Investigative Site

Osaka · Osaka · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
437

Novartis Investigative Site

Sayama · Saitama · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
438

Novartis Investigative Site

Ōmihachiman · Shiga · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
439

Novartis Investigative Site

Bunkyo Ku · Tokyo · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
440

Novartis Investigative Site

Chuo Ku · Tokyo · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
441

Novartis Investigative Site

Chuo-ku · Tokyo · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
442

Novartis Investigative Site

Hachiōji · Tokyo · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
443

Novartis Investigative Site

Itabashi-ku · Tokyo · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
444

Novartis Investigative Site

Ishikawa · Japan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
445

Novartis Investigative Site

Apeldoorn · Gelderland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
446

Novartis Investigative Site

Arnhem · Gelderland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
447

Novartis Investigative Site

Nijmegen · Gerlderland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
448

Novartis Investigative Site

Tiel · Gelderland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
449

Novartis Investigative Site

Heerlen · Limburg · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
450

Novartis Investigative Site

Tilburg · North Brabant · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
451

Novartis Investigative Site

Alkmaar · North Holland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
452

Novartis Investigative Site

Heemstede · North Holland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
453

Novartis Investigative Site

Deventer · Overijssel · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
454

Novartis Investigative Site

Zwolle · Overijssel · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
455

Novartis Investigative Site

Sneek · Provincie Friesland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
456

Novartis Investigative Site

Groningen · Provincie Groningen · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
457

Novartis Investigative Site

Leiden · South Holland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
458

Novartis Investigative Site

Leiderdorp · South Holland · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
459

Novartis Investigative Site

Amersfoort · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
460

Novartis Investigative Site

Enschede · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
461

Novartis Investigative Site

Gouda · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
462

Novartis Investigative Site

Hardenberg · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
463

Novartis Investigative Site

Utrecht · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
464

Novartis Investigative Site

Venlo · Netherlands

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
465

Novartis Investigative Site

Oslo · Norway

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
466

Novartis Investigative Site

Bielsko-Biala · Poland

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
467

Novartis Investigative Site

Chrzanów · Poland

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
468

Novartis Investigative Site

Gdansk · Poland

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
469

Novartis Investigative Site

Gdynia · Poland

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
470

Novartis Investigative Site

Lodz · Poland

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
471

Novartis Investigative Site

Tarnów · Poland

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
472

Novartis Investigative Site

Guimarães · Portugal

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
473

Novartis Investigative Site

Setúbal · Portugal

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
474

Research and Cardiovascular Corp

Ponce · Puerto Rico

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
475

Novartis Investigative Site

Buzău · Buzău · Romania

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
476

Novartis Investigative Site

Craiova · Dolj · Romania

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
477

Novartis Investigative Site

Baia Mare · Maramureş · Romania

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
478

Novartis Investigative Site

Bucharest · Romania

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
479

Novartis Investigative Site

Saint Petersburg · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
480

Novartis Investigative Site

Chelyabinsk · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
481

Novartis Investigative Site

Ivanovo · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
482

Novartis Investigative Site

Izhevsk · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
483

Novartis Investigative Site

Kemerovo · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
484

Novartis Investigative Site

Kirov · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
485

Novartis Investigative Site

Krasnodar · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
486

Novartis Investigative Site

Moscow · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
487

Novartis Investigative Site

Novosibirsk · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
488

Novartis Investigative Site

Perm · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
489

Novartis Investigative Site

Rostov-on-Don · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
490

Novartis Investigative Site

Ryazan · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
491

Novartis Investigative Site

Samara · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
492

Novartis Investigative Site

Saratov · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
493

Novartis Investigative Site

Sochy · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
494

Novartis Investigative Site

Tomsk · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
495

Novartis Investigative Site

Ulyanovsk · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
496

Novartis Investigative Site

Vsevolozhsk · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
497

Novartis Investigative Site

Yaroslavl · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
498

Novartis Investigative Site

Yekaterinburg · Russia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
499

Novartis Investigative Site

Košice · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
500

Novartis Investigative Site

Trnava · Slovakia · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
501

Novartis Investigative Site

Bardejov · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
502

Novartis Investigative Site

Bratislava · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
503

Novartis Investigative Site

Handlová · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
504

Novartis Investigative Site

Komárno · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
505

Novartis Investigative Site

Lučenec · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
506

Novartis Investigative Site

Nitra · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
507

Novartis Investigative Site

Nové Zámky · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
508

Novartis Investigative Site

Piešťany · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
509

Novartis Investigative Site

Považská Bystrica · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
510

Novartis Investigative Site

Prešov · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
511

Novartis Investigative Site

Rimavská Sobota · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
512

Novartis Investigative Site

Svidník · Slovakia

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
513

Novartis Investigative Site

Cape Town · South Africa

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
514

Novartis Investigative Site

Daegu · Dalseo gu · South Korea

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
515

Novartis Investigative Site

Wŏnju · Gangwon-do · South Korea

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
516

Novartis Investigative Site

Bundang Gu · Gyeonggi-do · South Korea

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
517

Novartis Investigative Site

Suwon · Gyeonggi-do · South Korea

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
518

Novartis Investigative Site

Incheon · Korea · South Korea

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
519

Novartis Investigative Site

Seoul · South Korea

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
520

Novartis Investigative Site

Busan · South Korea

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
521

Novartis Investigative Site

Gwangju · South Korea

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
522

Novartis Investigative Site

Seville · Spain

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
523

Novartis Investigative Site

Badalona · Barcelona · Spain

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
524

Novartis Investigative Site

L'Hospitalet de Llobregat · Barcelona · Spain

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
525

Novartis Investigative Site

Santander · Cantabria · Spain

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
526

Novartis Investigative Site

Reus · Tarragona · Spain

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
527

Novartis Investigative Site

Málaga · Spain

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
528

Novartis Investigative Site

Zaragoza · Spain

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
529

Novartis Investigative Site

Lund · Sweden

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
530

Novartis Investigative Site

Bern · Switzerland

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
531

Novartis Investigative Site

Liestal · Switzerland

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
532

Novartis Investigative Site

Taichung · Taiwan ROC · Taiwan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
533

Novartis Investigative Site

Hsinchu · Taiwan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
534

Novartis Investigative Site

Keelung · Taiwan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
535

Novartis Investigative Site

Taoyuan · Taiwan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
536

Novartis Investigative Site

Yilan · Taiwan

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
537

Novartis Investigative Site

Izmir · Turkey (Türkiye)

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
538

Novartis Investigative Site

Ankara · Bilkent-Cankaya · Turkey (Türkiye)

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
539

Novartis Investigative Site

Istanbul · Kadikoy · Turkey (Türkiye)

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
540

Novartis Investigative Site

Samsun · Samsun · Turkey (Türkiye)

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
541

Novartis Investigative Site

Eskişehir · Odunpazari · Turkey (Türkiye)

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
542

Novartis Investigative Site

Mersin · Yenisehir · Turkey (Türkiye)

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
543

Novartis Investigative Site

Dorchester · Dorset · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
544

Novartis Investigative Site

Preston · Lancashire · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
545

Novartis Investigative Site

Harrow · Middlesex · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
546

Novartis Investigative Site

Rochdale · North Manchester · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
547

Novartis Investigative Site

Taunton · Somerset · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
548

Novartis Investigative Site

Chertsey · Surrey · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
549

Novartis Investigative Site

Newcastle upon Tyne · Tyne and Wear · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
550

Novartis Investigative Site

Sunderland · Tyne and Wear · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
551

Novartis Investigative Site

Cardiff · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
552

Novartis Investigative Site

Birmingham · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
553

Novartis Investigative Site

Bristol · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
554

Novartis Investigative Site

Bromwich · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
555

Novartis Investigative Site

Chesterfield · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
556

Novartis Investigative Site

Glasgow · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
557

Novartis Investigative Site

Leicester · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
558

Novartis Investigative Site

Liverpool · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
559

Novartis Investigative Site

Middlesex · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
560

Novartis Investigative Site

Newport · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
561

Novartis Investigative Site

Plymouth · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
562

Novartis Investigative Site

Rhyl · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
563

Novartis Investigative Site

Sheffield · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
564

Novartis Investigative Site

Wiltshire · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
565

Novartis Investigative Site

Wrexham · United Kingdom

2 trials
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
566

Birmingham Clinical Research

Birmingham · Alabama · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
567

310 Clinical Research

Inglewood · California · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
568

Interventional Cardiology Medical Group

West Hills · California · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
569

IMA Clinical Research

Monroe · Louisiana · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
570

Monroe Research LLC

West Monroe · Louisiana · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
571

Metropolitan Cardiovascular Consultants LLC

Beltsville · Maryland · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
572

Centennial Medical Group

Columbia · Maryland · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
573

Capitol Cardiology Associates

Lanham · Maryland · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
574

Icahn School of Medicine at Mount Sinai

New York · New York · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
575

Ima Clinical Research Manhattan

New York · New York · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
576

Medical University of South Carolina

Charleston · South Carolina · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
577

Zenos Clinical Research

Dallas · Texas · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
578

Ima Clinical Research San Antonio

San Antonio · Texas · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
579

Rainier Clinical Research Center

Renton · Washington · United States

2 trials
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
580

Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC

Gilbert · Arizona · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
581

Clinical Research Institute of Arizona (CRI) - Sun City West

Sun City West · Arizona · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
582

Pima Heart

Tucson · Arizona · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
583

Neighborhood Healthcare Institute of Health

Escondido · California · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
584

Care Access - Huntington Beach

Huntington Beach · California · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
585

UCLA South Bay Endocrinology

Torrance · California · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
586

University of Colorado Anschutz Medical Campus

Aurora · Colorado · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
587

Cardiology Associates of Fairfield County, P.C.

Stamford · Connecticut · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
588

Chase Medical Research, LLC

Waterbury · Connecticut · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
589

K2 Medical Research - Maitland

Maitland · Florida · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
590

Advanced Research for Health Improvement, LLC

Naples · Florida · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
591

Renstar Medical Research

Ocala · Florida · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
592

Care Access - Tamarac

Tamarac · Florida · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
593

Care Access - Tampa

Tampa · Florida · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
594

Southeastern Clinical Research Institute

Augusta · Georgia · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
595

Center for Advanced Research & Education

Gainesville · Georgia · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
596

Great Lakes Clinical Trials - Ravenswood

Chicago · Illinois · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
597

Indiana University Health Methodist Hospital

Indianapolis · Indiana · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
598

Flourish Research - Bowie

Bowie · Maryland · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
599

Brigham and Women's Hospital Diabetes Program

Boston · Massachusetts · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
600

Care Access - Quincy

Quincy · Massachusetts · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
601

Revival Research Institute, LLC

Dearborn · Michigan · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
602

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

Troy · Michigan · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
603

Mercury Street Medical Group, PLLC

Butte · Montana · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Weekly alirocumab injections lower cholesterol in adults with high blood cholesterol levels.
Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗
604

Cardio Metabolic Institute

Somerset · New Jersey · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
605

IMA Clinical Research

Albuquerque · New Mexico · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
606

Care Access - Fayetteville

Fayetteville · North Carolina · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
607

Medication Management

Greensboro · North Carolina · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
608

Lehigh Valley Health Network

Allentown · Pennsylvania · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
609

Capital Area Research, LLC

Camp Hill · Pennsylvania · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
610

Penn Medicine: University of Pennsylvania Health System

Philadelphia · Pennsylvania · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
611

Clinical Research of Philadelphia

Philadelphia · Pennsylvania · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
612

Keystone Clinical Studies

Plymouth Meeting · Pennsylvania · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
613

PharmaTex Research

Amarillo · Texas · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
614

Texas Health Research & Education Institute - Fort Worth

Fort Worth · Texas · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
615

Center for Cardiometabolic Disease Prevention/Baylor College of Medicine

Houston · Texas · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
616

Research Physicians Network, LLC

Houston · Texas · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
617

Biopharma Informatic, LLC

McAllen · Texas · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
618

Revival Research Institute, LLC

McKinney · Texas · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
619

PRX Research

Mesquite · Texas · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
620

Sherman Clinical Research

Sherman · Texas · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
621

Clinical Investigation Specialists

Kenosha · Wisconsin · United States

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
622

Buenos Aires Macula S.A

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
623

Instituto Médico Especializado (IME)

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
624

Consultorio Medico Dr Litvak Bruno

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
625

Consultorio Medico Investigador Principal Dr Besada

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
626

Stat Research S.A.

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
627

Investigaciones Medicas Imoba Srl

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
628

Centro de Investigaciones Metabólicas (CINME)

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
629

CIPREC

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
630

CEMEDIC

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
631

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
632

Fundación Respirar

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
633

Centro Médico Arsema

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
634

Glenny Corp. S.A.

Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
635

IDIM - Instituto de Investigaciones Metabólicas

Ciudad de Buenos Aires · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
636

Instituto de Cardiología "Juana F. Cabral"

Corrientes · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
637

Instituto de Investigaciones Clínicas Córdoba

Córdoba · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
638

Centro Médico Colón

Córdoba · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
639

CIPADI - Centro Integral de Prevencion y Atencion en Diabetes

Godoy Cruz · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
640

Centro de Investigaciones Clínicas Baigorria

Granadero Baigorria · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
641

CIMeL

Lanus · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
642

Centro de Investigaciones Médicas Mar del Plata

Mar del Plata · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
643

Instituto de Investigaciones Clínicas Mar del Plata

Mar del Plata · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
644

Instituto de Cardiología Wolff

Mendoza · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
645

Instituto De Investigaciones Clinicas Quilmes

Quilmes · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
646

DIM Clínica Privada

Ramos Mejía · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
647

Instituto Médico Río Cuarto

Río Cuarto · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
648

Fundacion Estudios Clinicos

Rosario · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
649

INECO Neurociencias Oroño

Rosario · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
650

Instituto Especialidades de la Salud Rosario

Rosario · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
651

Instituto Médico Catamarca IMEC

Rosario · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
652

Instituto de Investigaciones Clinicas Rosario

Rosario · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
653

Laboratorio de Hemostasia y Trombosis

Rosario · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
654

Hospital Provincial del Centenario

Rosario · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
655

Corporación Médica San Martín

San Martin · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
656

Centro Modelo de Cardiología

San Miguel de Tucumán · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
657

Investigaciones Clínicas Tucumán

San Miguel de Tucumán · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
658

Centro de Diagnóstico y Rehabilitación (CEDIR)

Santa Fe · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
659

Centro de Investigaciones Clinicas del Litoral

Santa Fe · Argentina

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
660

Box Hill Hospital

Box Hill · Australia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
661

Royal Brisbane and Women's Hospital

Brisbane · Australia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
662

Heart of Australia

Brisbane · Australia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
663

Barwon Health

Geelong · Australia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
664

University of the Sunshine Coast (UniSC) Clinical Trials - Meadowbrook

Meadowbrook · Australia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
665

The AIM Centre / Hunter Diabetes Centre

Merewether · Australia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
666

USC Clinical Trials Moreton Bay

Morayfield · Australia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
667

USC Clinical Trials Sunshine Coast

Sippy Downs · Australia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
668

Krankenhaus St. Josef Braunau

Braunau am Inn · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
669

VIVIT

Feldkirch · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
670

Ordensklinikum Linz GmbH Elisabethinen

Linz · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
671

Konventhospital der Barmherzigen Brüder Linz

Linz · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
672

Landesklinikum Mistelbach

Mistelbach · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
673

Uniklinikum Salzburg

Salzburg · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
674

Universitätsklinikum St. Pölten

Sankt Pölten · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
675

Klinik Landstraße

Vienna · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
676

Zentrum für klinische Studien Dr Hanusch Gmbh

Vienna · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
677

Medizinische Universität Wien

Vienna · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
678

Universitaetsklinikum Allgemeines Krankenhaus Wien

Vienna · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
679

Klinik Hietzing

Vienna · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
680

Herz Zentrum Währing - Innere Medizin und Kardiologie | Alle Kassen und Privat

Vienna · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
681

Klinik Floridsdorf

Vienna · Austria

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
682

ZAS Middelheim

Antwerp · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
683

Imelda General Hospital

Bonheiden · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
684

Algemeen Ziekenhuis klina

Brasschaat · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
685

Centre Hospitalier Universitaire Brugmann

Brussels · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
686

Cliniques universitaires Saint-Luc

Brussels · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
687

Antwerp University Hospital

Edegem · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
688

Ziekenhuis Oost-Limburg, Campus St.-Jan

Genk · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
689

AZ Groeninge Campus Kennedylaan

Kortrijk · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
690

UZ Leuven

Leuven · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
691

AZ Sint-Maarten

Mechelen · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
692

AZ Oostende vzw

Ostend · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
693

AZ Delta vzw

Roeselare · Belgium

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
694

Centro de Pesquisa Clinica do Coracao

Aracaju · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
695

Hospital Universitário João de Barros Barreto

Belém · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
696

NUPEC - Cardio

Belo Horizonte · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
697

AngioKormann Blumenau

Blumenau · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
698

Chronos Pesquisa Clínica

Brasília · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
699

Instituto de Pesquisa clinica de Campinas

Campinas · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
700

Centro de Pesquisa Sao Lucas

Campinas · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
701

Quanta Diagnóstico e Terapia

Curitiba · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
702

Universidade Federal de Goias

Goiânia · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
703

Instituto Do Coracao De Marilia

Marília · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
704

Instituto Méderi de Pesquisa e Saúde

Passo Fundo · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
705

Hospital de Clinicas de Porto Alegre

Porto Alegre · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
706

Hospital Moinhos de Vento

Porto Alegre · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
707

Núcleo de Pesquisa Clínica do Rio Grande do Sul

Porto Alegre · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
708

Hospital Nossa Senhora da Conceição

Porto Alegre · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
709

IBPClin - Instituto Brasil de Pesquisa Clínica

Rio de Janeiro · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
710

Ruschel Medicina e Pesquisa Clínica

Rio de Janeiro · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
711

Praxis Pesquisa Medica

Santo André · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
712

Fundação Faculdade Regional de Medicina de São José do Rio Preto

São José do Rio Preto · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
713

Centro Internacional de Pesquisa Clínica (CIPES)

São José dos Campos · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
714

CPQuali Pesquisa Clínica

São Paulo · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
715

CPCLIN

São Paulo · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
716

Instituto Dante Pazzanese de Cardiology

São Paulo · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
717

CEPIC - Centro Paulista de Investigação Clínica

São Paulo · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
718

Incor - Instituto do Coracao

São Paulo · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
719

CEDOES

Vitória · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
720

Integral Pesquisa e Ensino

Votuporanga · Brazil

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
721

Diex Recherche Inc. Division Joliette

Joliette · Canada

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3SUSPENDEDNCT07157774 ↗
722

Viacar Recherche Clinique

Longueuil · Canada

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
723

G A Research Associates

Moncton · Canada

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
724

Diex Recherche Inc. Division Trois-Rivieres

Trois-Rivières · Canada

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3SUSPENDEDNCT07157774 ↗
725

Discovery Clinical Services

Victoria · Canada

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
726

Peking University Third Hospital

Beijing · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
727

The First Hospital of Jilin University

Changchun · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
728

China-Japan Union Hospital

Changchun · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
729

Changde First People's Hospital

Changde · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
730

Sichuan Provincial People's Hospital

Chengdu · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
731

West China Hospital Sichuan University

Chengdu · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
732

2nd Affiliated Hospital Chongqing Medical Universi

Chongqing · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
733

Guangdong Provincial People's Hospital

Guangzhou · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
734

Zhejiang Provincial People's Hospital

Hangzhou · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
735

The First Hospital of Harbin Medical University

Harbin · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
736

The Second People's Hospital of Hefei

Hefei · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
737

Jinan Central Hospital

Jinan · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
738

Lishui Central Hospital

Lishui · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
739

The First Affiliated Hospital of Henan University of Science &Technology

Luoyang · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
740

Zhongshan Hospital,Fudan University

Shanghai · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
741

Siping Central People's Hospital

Siping · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
742

Chongqing Three Gorges Central Hospital

Wanzhou · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
743

Renmin Hospital of Wuhan University

Wuhan · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
744

Shaanxi provincial people's hospital

Xi'an · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
745

The Affiliated Hospital of Xuzhou Medical College

Xuzhou · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
746

Zigong First People's Hospital

Zigong · China

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
747

Kardiologická ambulance Brno

Brno · Czechia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
748

Angiocentrum Komorany

Prague · Czechia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
749

Poliklinika Lípa Centrum

Prague · Czechia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
750

Cardio Research, s.r.o

Zlín · Czechia

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
751

Sanos Clinic - Nordjylland

Gandrup · Denmark

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
752

Sanos Clinic

Herlev · Denmark

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
753

Sanos Clinic - Syddanmark

Vejle · Denmark

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
754

Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand

Dijon · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
755

Hopital Claude Huriez - CHU de Lille

Lille · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
756

Centre Hospitalier Saint Joseph - Saint Luc

Lyon · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
757

Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes

Nantes · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
758

Centre Hospitalier Universitaire de Nice - Hopital Pasteur

Nice · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
759

Pitie Salpetriere University Hospital

Paris · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
760

Hôpital Européen Georges Pompidou

Paris · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
761

Hôpital Bichat - Claude-Bernard

Paris · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
762

Hôpital Saint Antoine

Paris · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
763

CHU Strasbourg-Hautepierre

Strasbourg · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
764

CHU Rangueil

Toulouse · France

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
765

Universitätsklinikum Aachen

Aachen · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
766

Zentrum für klinische Studien Bad Homburg

Bad Homburg · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
767

Kardiologische Praxen im Spreebogen

Berlin · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
768

Charité Campus Virchow-Klinikum

Berlin · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
769

Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien

Dresden · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
770

Herzzentrum Dresden GmbH Universitätsklinik

Dresden · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
771

Universitaetsklinikum Carl Gustav Carus Dresden

Dresden · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
772

Cardioangiologisches Centrum Bethanien

Frankfurt · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
773

Cardiologicum Hamburg

Hamburg · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
774

Universitaetsklinikum Heidelberg

Heidelberg · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
775

Universitätsklinikum Leipzig

Leipzig · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
776

Herzzentrum Leipzig GmbH

Leipzig · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
777

Praxis Oedeme

Lüneburg · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
778

Otto-von-Guericke-Universität Magdeburg

Magdeburg · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
779

ze:ro ARZTPRAXEN

Mannheim · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
780

Deutsches Herzzentrum München

Munich · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
781

Institut für Diabetesforschung GmbH Münster

Münster · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
782

Universitätsklinikum Regensburg

Regensburg · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
783

Studienzentrum Herzklinik Ulm MVZ

Ulm · Germany

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
784

University General Hospital of Heraklion

Heraklion · Greece

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
785

University Hospital of Ioannina

Ioannina · Greece

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
786

AHEPA University General Hospital of Thessaloniki

Thessaloniki · Greece

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
787

Medifarma 98 Kft

Nyíregyháza · Hungary

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
788

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

Szeged · Hungary

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
789

Vita Verum Medical Egeszsegugyi Szolgaltato

Székesfehérvár · Hungary

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
790

KLES Dr. Prabhakar Kore Hospital & M.R.C

Belagavi · India

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
791

K care Hospital

Kanpur · India

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
792

Government Medical College - Kozhikode

Kozhikode · India

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
793

King George's Medical University

Lucknow · India

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
794

Vijan Hospital & Research Centre

Nashik · India

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
795

G.B. Pant Institute of Postgraduate Medical Education & Research

New Delhi · India

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
796

All India Institute of Medical Sciences

Raipur · India

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
797

Ospedale Cazzavillan di Arzignano

Arzignano · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
798

Ospedale di Baggiovara

Baggiovara · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
799

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

Bologna · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
800

Azienda Ospedaliero Universitaria S.Anna

Ferrara · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
801

Azienda Ospedaliera Universitaria Careggi

Florence · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
802

Ospedale San Martino

Genova · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
803

Centro Cardiologico Monzino

Milan · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
804

ASST Grande Ospedale Metropolitano Niguarda

Milan · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
805

Ospedale San Raffaele

Milan · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
806

Azienda Ospedale - Università Padova

Padova · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
807

Hospital Santa Maria della Misericordia in Perugia

Perugia · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
808

Fondazione G. Monasterio

Pisa · Italy

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
809

The Institute of Medical Science, Asahi Life Foundation

Chūōku · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
810

Hakodate Municipal Hospital

Hakodate · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
811

Tenyoukai Central Clinic

Kagoshima · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
812

Kanazawa University Hospital

Kanazawa · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
813

Miyazaki Medical Association Hospital

Miyazaki · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
814

Iwate Prefectural Central Hospital

Morioka · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
815

Nagoya City University Hospital

Nagoya · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
816

Osaka Keisatsu Hospital

Osaka · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
817

Osaka General Medical Center

Osaka · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
818

Sapporo Medical University Hospital

Sapporo · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
819

Japan Community Healthcare Organization Hokkaido Hospital

Sapporo · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
820

Tokuyama Central Hospital

Shūnan · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
821

National Cerebral and Cardiovascular Center

Suita · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
822

Kagawa Prefectural Central Hospital

Takamatsu · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
823

Osaka Medical and Pharmaceutical University Hospital

Takatsuki · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
824

Sekino Hospital

Toshimaku · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
825

Tsuchiura Kyodo General Hospital

Tsuchiura · Japan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
826

Fundación Cardiovascular de Aguascalientes A.C.

Aguascalientes · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
827

Instituto de Diabetes, Obesidad y Nutricion

Cuernavaca · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
828

Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.

Culiacán · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
829

Instituto Jalisciense de Investigacion en Diabetes y Obesidad

Guadalajara · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
830

Unidad de Investigación Clínica y Atención Médica HEPA S.C.

Guadalajara · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
831

Virgen Cardiovascular Research SC

Guadalajara · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
832

Instituto Cardiovascular de León S.C.

León · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
833

Grupo Medico Camino Sc

Mexico City · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
834

Hospital de Jésus, I.A.P.

Mexico City · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
835

Centro Médico Nacional Siglo XXI

Mexico City · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
836

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Mexico City · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
837

Medical Care and Research SA de CV

Mérida · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
838

Accelerium Clinical Research

Monterrey · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
839

Cardiolink Clin Trials

Monterrey · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
840

UBAM Unidad Biomedica Avanzada Monterrey

Monterrey · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
841

Clínica García Flores SC

Monterrey · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
842

Centro de investigación y control metabólico

Monterrey · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
843

Centro de Atención e Investigación Cardiovascular del Potosí

San Luis Potosí City · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
844

Servicios Integrales Nova de Monterrey S.A. de C.V.

San Nicolás de los Garza · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
845

Medimanage Research

Tlalpan · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
846

Hospital Angeles Xalapa

Xalapa · Mexico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
847

Meander Medisch Centrum

Amersfoort · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
848

Amsterdam UMC, locatie AMC

Amsterdam · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
849

Ziekenhuis Gelderse Vallei

Ede · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
850

Tergooiziekenhuizen, locatie Hilversum

Hilversum · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
851

Leids Universitair Medisch Centrum

Leiden · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
852

Bravis Ziekenhuis, locatie Roosendaal

Roosendaal · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
853

Erasmus Medisch Centrum

Rotterdam · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
854

Universitair Medisch Centrum Utrecht

Utrecht · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
855

Maxima Medisch Centrum, locatie Veldhoven

Veldhoven · Netherlands

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
856

NZOZ Twoje Zdrowie EL Sp. z o. o.

Elblag · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
857

NZOZ Salvia CM

Katowice · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
858

Centrum Medyczne Linden

Krakow · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
859

Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET

Krakow · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
860

Poliklinika Kardiologiczna Serce

Leszno · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
861

Centra Medyczne Medyceusz

Lodz · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
862

Instytut Centrum Zdrowia Matki Polki

Lodz · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
863

Clinical Best Solutions

Lublin · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
864

Private Practice - Dr. Michał Tomaszewski

Lublin · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
865

Centrum Szybkiej Diagnostyki Kardiologicznej "Kardiomed" M. Żabówka E. Żabówka

Tarnów · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
866

4 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ

Wroclaw · Poland

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
867

Advanced Clinical Research, LLC

Bayamón · Puerto Rico

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
868

Nicodiab

Bucharest · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
869

Hightech Medical Services SRL-Centrul pentru Studiul Metabolismului

Bucharest · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
870

Centrul Medical NutriLife

Bucharest · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
871

Spitalul Universitar de Urgență București

Bucharest · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
872

Mat Cord Biomedica S.R.L.

Buzău · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
873

Milena Sante

Galați · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
874

Diamed Obesity

Galați · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
875

Clinica Korall

Satu Mare · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
876

Policlinica Astra Sibiu

Sibiu · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
877

SC Dentosim Queen SRL - Centrul Medical Diamed

Târgu Mureş · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
878

Centrul Medical Mediab

Târgu Mureş · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
879

Mediab S.R.L.

Târgu Mureş · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
880

Private Practice - Dr. Cristian Podoleanu

Târgu Mureş · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
881

Cabinet Medical Dr.Geru

Timișoara · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
882

Institutul de Boli Cardiovasculare Timișoara

Timișoara · Romania

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
883

Daegu Catholic University Medical Center

Daegu · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
884

Gachon University Gil Medical Center

Namdong-gu · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
885

Seoul National University Bundang Hospital

Seongnam · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
886

Korea University Anam Hospital

Seoul · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
887

Kangbuk Samsung Hospital

Seoul · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
888

Severance Hospital, Yonsei University Health System

Seoul · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
889

Asan Medical Center

Seoul · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
890

The Catholic Univ. of Korea Seoul St. Mary's Hospital

Seoul · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
891

Korea University Guro Hospital

Seoul · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
892

The Catholic University Of Korea St. Vincent's Hospital

Suwon · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
893

Ulsan University Hospital

Ulsan · South Korea

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
894

Hospital Clínic de Barcelona

Barcelona · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
895

Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval

Ferrol · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
896

Hospital Universitario Virgen Nieves

Granada · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
897

Hospital Infanta Elena

Huelva · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
898

Hospital Universitario de Jaen

Jaén · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
899

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
900

FutureMeds - Madrid

Madrid · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
901

Hospital Universitario 12 de Octubre

Madrid · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
902

Hospital Universitario Virgen de la Victoria

Málaga · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
903

Hospital Universitari Son Espases

Palma · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
904

Salut Sant Joan de Reus-Baix Camp (Edp)

Reus · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
905

Hospital Virgen del Camino

Sanlúcar de Barrameda · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
906

Hospital Universitario Marqués de Valdecilla

Santander · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
907

CHUS - Hospital Clinico Universitario

Santiago de Compostela · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
908

Hospital General de Segovia

Segovia · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
909

FutureMeds - Sevilla

Seville · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
910

Vithas Hospital Sevilla

Seville · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
911

Hospital Clinico de Valencia

Valencia · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
912

Hospital Virgen de las Montañas

Villamartín · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
913

Hospital Universitario Miguel Servet

Zaragoza · Spain

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
914

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
915

Chang Gung Memorial Hospital at Kaohsiung

Kaohsiung Niao Sung Dist · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
916

Chi Mei Medical Center

Tainan · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
917

National Taiwan University Hospital

Taipei · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
918

Cathay General Hospital

Taipei · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
919

Taipei Medical University Hospital

Taipei · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
920

Shin Kong Wu Ho-Su Memorial Hospital

Taipei · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
921

Taipei Veterans General Hospital

Taipei · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
922

Tri-Service General Hospital

Taipei · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
923

Chang Gung Medical Foundation-Linkou Branch

Taoyuan · Taiwan

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
924

Layton Medical Centre

Blackpool · United Kingdom

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
925

Panthera Biopartners - North London

Enfield · United Kingdom

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
926

Panthera Biopartners - Preston

Preston · United Kingdom

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
927

Panthera Biopartners - Manchester

Rochdale · United Kingdom

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
928

Panthera Biopartners - Sheffield

Sheffield · United Kingdom

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
929

Sandwell General Hospital

West Bromwich · United Kingdom

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
930

Panthera Clinic - York

York · United Kingdom

2 trials
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
931

Parkway Medical Center

Birmingham · Alabama · United States

2 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
932

SEC Clinical Research

Pensacola · Florida · United States

2 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
933

AB Clinical Trials

Las Vegas · Nevada · United States

2 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
934

Novartis Investigative Site

Pessac · France

2 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
935

Novartis Investigative Site

Poitiers · France

2 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
936

Novartis Investigative Site

Caserta · CE · Italy

2 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
937

Novartis Investigative Site

Pordenone · PN · Italy

2 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
938

Novartis Investigative Site

Salamanca · Spain

2 trials
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
939

Flourish Res Acq LLC North Miami

Miami · Florida · United States

2 trials
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
940

Novartis Investigative Site

Kaiserslautern · Rhineland-Palatinate · Germany

2 trials
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
941

Capital Cardiology Associates

Albany · New York · United States

2 trials
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
942

Novartis Investigative Site

Zhengzhou · Henan · China

2 trials
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
943

Merritt Island Medical Research, LLC

Merritt Island · Florida · United States

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
944

Clinical Site Partners, LLC dba Flourish Research

Winter Park · Florida · United States

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
945

Profound Research LLC

Farmington Hills · Michigan · United States

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
946

Virginia Heart - Leesburg

Leesburg · Virginia · United States

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
947

University of the Sunshine Coast (UniSC) Clinical Trials - Birtinya

Birtinya · Australia

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
948

Top Moravia Health

Brno · Czechia

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
949

Szabolcs Szatmár Bereg Vármegyei Oktatókórház

Nyíregyháza · Hungary

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
950

Medisch Spectrum Twente

Enschede · Netherlands

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
951

Alrijne Ziekenhuis, locatie Leiderdorp

Leiderdorp · Netherlands

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
952

Hospital Quiron Barcelona

Barcelona · Spain

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
953

FutureMeds - Birmingham

Birmingham · United Kingdom

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
954

Royal Lancaster Infirmary

Lancaster · United Kingdom

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
955

Lincoln County Hospital

Lincoln · United Kingdom

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
956

Futuremeds-Newcastle

Newcastle · United Kingdom

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
957

The John Radcliffe Hospital

Oxford · United Kingdom

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
958

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield · United Kingdom

1 trial
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
959

Clinical Study Center

Dothan · Alabama · United States

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
960

Clinical Study Center

Pomona · California · United States

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
961

Clinical Study Center

Boca Raton · Florida · United States

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
962

Clinical Study Center

Jacksonville · Florida · United States

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
963

Clinical Study Center

Winter Park · Florida · United States

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
964

Clinical Study Center

High Point · North Carolina · United States

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
965

Clinical Study Center

DeSoto · Texas · United States

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
966

Clinical Study Center

Renton · Washington · United States

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
967

Clinical Study Center

Adelaide · Australia

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
968

Clinical Study Center

Melbourne · Australia

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
969

Clinical Study Center

Sydney · Australia

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
970

Clinical Study Center

Chicoutimi · Canada

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
971

Clinical Study Center

Montreal · Canada

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
972

Clinical Study Center

Québec · Canada

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
973

Clinical Study Center

Toronto · Canada

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
974

Clinical Study Center

Vancouver · Canada

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
975

Clinical Study Center

Rehovot · Israel

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
976

Clinical Study Center

Christchurch · New Zealand

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
977

Clinical Study Center

Birmingham · United Kingdom

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
978

Clinical Study Center

Edinburgh · United Kingdom

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
979

Clinical Study Center

London · United Kingdom

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
980

Clinical Study Center

Manchester · United Kingdom

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
981

Clinical Study Center

Nottingham · United Kingdom

1 trial
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
982

University of Central Florida

Orlando · Florida · United States

1 trial
Study measures how common elevated lipoprotein(a) is in primary care patients to improve heart disease screening.
University of Central FloridaRecruitingNCT07579325 ↗
983

Grandview Med Group Research LLC

Birmingham · Alabama · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
984

Novartis Investigative Site

Birmingham · Alabama · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
985

Novartis Investigative Site

Huntsville · Alabama · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
986

Novartis Investigative Site

Mobile · Alabama · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
987

Novartis Investigative Site

Cottonwood · Arizona · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
988

Novartis Investigative Site

Sun City West · Arizona · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
989

Novartis Investigative Site

Tucson · Arizona · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
990

Novartis Investigative Site

Little Rock · Arkansas · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
991

Novartis Investigative Site

Beverly Hills · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
992

Novartis Investigative Site

Covina · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
993

Diabetes Lipid Management Center

Huntington Beach · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
994

Novartis Investigative Site

Huntington Beach · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
995

Novartis Investigative Site

La Jolla · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
996

Memorial Care Health System

Long Beach · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
997

Novartis Investigative Site

Long Beach · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
998

Novartis Investigative Site

Los Angeles · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
999

Novartis Investigative Site

Northridge · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1000

Novartis Investigative Site

Orange · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1001

Novartis Investigative Site

San Francisco · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1002

Novartis Investigative Site

Santa Ana · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1003

Novartis Investigative Site

Stanford · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1004

Novartis Investigative Site

Stockton · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1005

Novartis Investigative Site

West Hills · California · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1006

Novartis Investigative Site

Aurora · Colorado · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1007

Novartis Investigative Site

Bridgeport · Connecticut · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1008

Novartis Investigative Site

Hartford · Connecticut · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1009

Novartis Investigative Site

Waterbury · Connecticut · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1010

Novartis Investigative Site

Boca Raton · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1011

Cardiovascular and Vein Center of Florida

Bradenton · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1012

Novartis Investigative Site

Bradenton · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1013

Novartis Investigative Site

Brandon · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1014

Novartis Investigative Site

Fort Lauderdale · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1015

CV Consultants of South Broward

Hollywood · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1016

Novartis Investigative Site

Jacksonville · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1017

East Coast Institute for Research

Jacksonville · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1018

Infinite Clinical Research

Miami · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1019

Novartis Investigative Site

Miami · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1020

Novartis Investigative Site

Naples · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1021

Southwest Florida Research

Naples · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1022

Novartis Investigative Site

Port Charlotte · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1023

Novartis Investigative Site

Port Orange · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1024

Novartis Investigative Site

Saint Augustine · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1025

Novartis Investigative Site

Wellington · Florida · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1026

Novartis Investigative Site

Atlanta · Georgia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1027

Grady Health System

Atlanta · Georgia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1028

Novartis Investigative Site

Dunwoody · Georgia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1029

Alta Pharmaceutical Research Center

Peachtree Corners · Georgia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1030

Novartis Investigative Site

Thomasville · Georgia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1031

Novartis Investigative Site

Park Ridge · Illinois · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1032

Novartis Investigative Site

Indianapolis · Indiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1033

Novartis Investigative Site

Iowa City · Iowa · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1034

Novartis Investigative Site

Kansas City · Kansas · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1035

Novartis Investigative Site

Topeka · Kansas · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1036

Christus Health Central Louisiana

Alexandria · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1037

Novartis Investigative Site

Alexandria · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1038

Novartis Investigative Site

Baton Rouge · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1039

Novartis Investigative Site

Bogalusa · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1040

Novartis Investigative Site

Bossier City · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1041

Novartis Investigative Site

Covington · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1042

Novartis Investigative Site

Eunice · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1043

Heart Clinic of Hammond

Hammond · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1044

Novartis Investigative Site

Hammond · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1045

Novartis Investigative Site

Houma · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1046

Novartis Investigative Site

Metairie · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1047

Tulane Uni Health Sciences Center

New Orleans · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1048

Crescent City Physicians Inc

New Orleans · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1049

Novartis Investigative Site

New Orleans · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1050

Novartis Investigative Site

Opelousas · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1051

Novartis Investigative Site

Shreveport · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1052

Novartis Investigative Site

Slidell · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1053

Novartis Investigative Site

Zachary · Louisiana · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1054

Novartis Investigative Site

Scarborough · Maine · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1055

Novartis Investigative Site

Baltimore · Maryland · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1056

University of Maryland

Baltimore · Maryland · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1057

Novartis Investigative Site

Columbia · Maryland · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1058

Novartis Investigative Site

Ft. Washington · Maryland · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1059

Novartis Investigative Site

Rockville · Maryland · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1060

Novartis Investigative Site

Boston · Massachusetts · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1061

Novartis Investigative Site

Detroit · Michigan · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1062

Novartis Investigative Site

Flint · Michigan · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1063

Genesys Regional Medical Center

Grand Blanc · Michigan · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1064

Novartis Investigative Site

Grand Blanc · Michigan · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1065

Novartis Investigative Site

Kalamazoo · Michigan · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1066

Novartis Investigative Site

Petoskey · Michigan · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1067

Novartis Investigative Site

Saginaw · Michigan · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1068

Novartis Investigative Site

Wyoming · Michigan · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1069

Novartis Investigative Site

Minneapolis · Minnesota · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1070

Novartis Investigative Site

Belzoni · Mississippi · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1071

Novartis Investigative Site

Southaven · Mississippi · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1072

Novartis Investigative Site

Yazoo City · Mississippi · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1073

Novartis Investigative Site

City of Saint Peters · Missouri · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1074

Novartis Investigative Site

St Louis · Missouri · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1075

Mercy South

St Louis · Missouri · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1076

Mercy Hospital St Louis

St Louis · Missouri · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1077

Novartis Investigative Site

Lincoln · Nebraska · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1078

Novartis Investigative Site

Omaha · Nebraska · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1079

Novartis Investigative Site

Lebanon · New Hampshire · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1080

Novartis Investigative Site

Ridgewood · New Jersey · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1081

Novartis Investigative Site

Summit · New Jersey · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1082

Novartis Investigative Site

Manhasset · New York · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1083

New York Uni Med Ctr

New York · New York · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1084

Novartis Investigative Site

New York · New York · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1085

Rochester Regional Health

Rochester · New York · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1086

Novartis Investigative Site

Southampton · New York · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1087

Novartis Investigative Site

Charlotte · North Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1088

Novartis Investigative Site

Greensboro · North Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1089

Novartis Investigative Site

High Point · North Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1090

Novartis Investigative Site

Sanford · North Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1091

Jones Family Practice PA

Shelby · North Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1092

Novartis Investigative Site

Shelby · North Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1093

Novartis Investigative Site

Winston-Salem · North Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1094

Novartis Investigative Site

Akron · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1095

Akron Hospital Summa Health System

Akron · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1096

Novartis Investigative Site

Canton · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1097

Novartis Investigative Site

Cincinnati · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1098

Velocity Clin Research Springdale

Cincinnati · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1099

University Of Cincinnati

Cincinnati · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1100

Novartis Investigative Site

Cleveland · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1101

Novartis Investigative Site

Columbus · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1102

Novartis Investigative Site

Marion · Ohio · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1103

Novartis Investigative Site

Portland · Oregon · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1104

Oregon Health Sciences University

Portland · Oregon · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1105

Novartis Investigative Site

Lancaster · Pennsylvania · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1106

Novartis Investigative Site

Philadelphia · Pennsylvania · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1107

Allegheny General Hospital

Pittsburgh · Pennsylvania · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1108

Novartis Investigative Site

Yardley · Pennsylvania · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1109

Miriam Hospital

Providence · Rhode Island · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1110

Novartis Investigative Site

Providence · Rhode Island · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1111

Novartis Investigative Site

Fort Mill · South Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1112

Piedmont Research Partners LLC

Fort Mill · South Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1113

Novartis Investigative Site

Summerville · South Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1114

Palmetto Clinical Research

Summerville · South Carolina · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1115

Novartis Investigative Site

Rapid City · South Dakota · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1116

Novartis Investigative Site

Germantown · Tennessee · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1117

Novartis Investigative Site

Jackson · Tennessee · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1118

Novartis Investigative Site

Nashville · Tennessee · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1119

Novartis Investigative Site

Powell · Tennessee · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1120

Novartis Investigative Site

Dallas · Texas · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1121

Novartis Investigative Site

Houston · Texas · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1122

Novartis Investigative Site

Livingston · Texas · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1123

Novartis Investigative Site

Temple · Texas · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1124

Novartis Investigative Site

Tomball · Texas · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1125

Novartis Investigative Site

Bountiful · Utah · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1126

Novartis Investigative Site

Murray · Utah · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1127

Novartis Investigative Site

Danville · Virginia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1128

Novartis Investigative Site

Falls Church · Virginia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1129

Novartis Investigative Site

Manassas · Virginia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1130

Novartis Investigative Site

Norfolk · Virginia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1131

Novartis Investigative Site

Richmond · Virginia · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1132

Novartis Investigative Site

Seattle · Washington · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1133

Novartis Investigative Site

Milwaukee · Wisconsin · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1134

St Luke s Medical Center Aurora

Milwaukee · Wisconsin · United States

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1135

Novartis Investigative Site

San Miguel Tucuman · Tucumán Province · Argentina

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1136

Novartis Investigative Site

Southport · Queensland · Australia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1137

Novartis Investigative Site

Maceió · Alagoas · Brazil

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1138

Novartis Investigative Site

Brasília · Federal District · Brazil

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1139

Novartis Investigative Site

Blagoevgrad · Bulgaria · Bulgaria

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1140

Novartis Investigative Site

Victoria · British Columbia · Canada

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1141

Novartis Investigative Site

Terrebonne · Quebec · Canada

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1142

Novartis Investigative Site

Santiago · Chile

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1143

Novartis Investigative Site

Svitavy · Czechia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1144

Novartis Investigative Site

Tourcoing · France

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1145

Novartis Investigative Site

Künzing · Bavaria · Germany

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1146

Novartis Investigative Site

Chalcis · Greece

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1147

Novartis Investigative Site

Guatemala City · Guatemala

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1148

Novartis Investigative Site

Shatin · Hong Kong

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1149

Novartis Investigative Site

Pécs · Baranya · Hungary

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1150

Novartis Investigative Site

Kistarcsa · Hungary

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1151

Novartis Investigative Site

Makó · Hungary

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1152

Novartis Investigative Site

Miskolc · Hungary

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1153

Novartis Investigative Site

Nyíregyháza · Hungary

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1154

Novartis Investigative Site

Székesfehérvár · Hungary

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1155

Novartis Investigative Site

Kopavogur · Iceland

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1156

Novartis Investigative Site

Reykjavik · Iceland

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1157

Novartis Investigative Site

Kozhikode · Kerala · India

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1158

Novartis Investigative Site

Mumbai · Maharashtra · India

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1159

Novartis Investigative Site

Varanasi · Uttar Pradesh · India

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1160

Novartis Investigative Site

Nagoya · Aichi-ken · Japan

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1161

Novartis Investigative Site

Fukuoka · Fukuoka · Japan

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1162

Novartis Investigative Site

Kahoku-gun · Ishikawa-ken · Japan

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1163

Novartis Investigative Site

Nagaoka · Niigata · Japan

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1164

Novartis Investigative Site

Kawaguchi · Saitama · Japan

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1165

Novartis Investigative Site

Ōta-ku · Tokyo · Japan

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1166

Novartis Investigative Site

Shinagawa-ku · Tokyo · Japan

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1167

Novartis Investigative Site

Toshima-ku · Tokyo · Japan

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1168

Novartis Investigative Site

Aguascalientes · Aguascalientes · Mexico

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1169

Novartis Investigative Site

Cuernavaca · Morelos · Mexico

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1170

Novartis Investigative Site

San Luis Potosí City · San Luis Potosí · Mexico

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1171

Novartis Investigative Site

Culiacan Sinaloa · Mexico

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1172

Novartis Investigative Site

Distrito Federal · Mexico

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1173

Novartis Investigative Site

Delft · South Holland · Netherlands

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1174

Novartis Investigative Site

Skedsmokorset · Norway

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1175

Novartis Investigative Site

San Miguel · Lima region · Peru

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1176

Novartis Investigative Site

Kędzierzyn-Koźle · Poland

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1177

Novartis Investigative Site

Krakow · Poland

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1178

Novartis Investigative Site

Poznan · Poland

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1179

Novartis Investigative Site

Sochaczew · Poland

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1180

Novartis Investigative Site

Ponce · Puerto Rico

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1181

Novartis Investigative Site

Iași · Romania

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1182

Novartis Investigative Site

Timișoara · Timiș County · Romania

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1183

Novartis Investigative Site

Brasov · Romania

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1184

Novartis Investigative Site

Petrozavodsk · Russia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1185

Novartis Investigative Site

Brezno · Slovakia · Slovakia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1186

Novartis Investigative Site

Banská Bystrica · Slovakia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1187

Novartis Investigative Site

Dolný Kubín · Slovakia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1188

Novartis Investigative Site

Kláštor pod Znievom · Slovakia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1189

Novartis Investigative Site

Rožňava · Slovakia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1190

Novartis Investigative Site

Žilina · Slovakia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1191

Novartis Investigative Site

Ljubljana · Slovenia

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1192

Novartis Investigative Site

Soweto · Gauteng · South Africa

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1193

Novartis Investigative Site

George · Western Cape · South Africa

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1194

Novartis Investigative Site

Gothenburg · Sweden

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1195

Novartis Investigative Site

Stockholm · Sweden

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1196

Novartis Investigative Site

Hardwick · Stockton on Tees · United Kingdom

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1197

Novartis Investigative Site

Bournemouth · United Kingdom

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1198

Novartis Investigative Site

Dundee · United Kingdom

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1199

Novartis Investigative Site

Swansea · United Kingdom

1 trial
Pelacarsen reduces cardiovascular events in patients with established heart disease and high lipoprotein(a).
Novartis PharmaceuticalsPh 3NCT04023552 ↗
1200

Chu de Nice

Nice · France · France

1 trial
Study investigates lipoprotein(a) levels in lymphedema patients as a cardiovascular risk factor.
Centre Hospitalier Universitaire de NiceRecruitingNCT05962827 ↗
1201

Centre antoine lacassagne

Nice · France · France

1 trial
Study investigates lipoprotein(a) levels in lymphedema patients as a cardiovascular risk factor.
Centre Hospitalier Universitaire de NiceTERMINATEDNCT05962827 ↗
1202

Allina Health

Minneapolis · Minnesota · United States

1 trial
Education program improves cholesterol testing and treatment in hospitalized heart attack patients.
Duke UniversityRecruitingNCT06471036 ↗
1203

Advanced Cardiovascular LLC

Alexander City · Alabama · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1204

University of Alabama Birmingham Saint Vincents Birmingham

Birmingham · Alabama · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1205

Alliance For Multispecialty Research - Daphne

Daphne · Alabama · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1206

Eastern Shore Research Institute

Fairhope · Alabama · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1207

CB Flock Research Corporation

Mobile · Alabama · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1208

Phoenix Clinical

Phoenix · Arizona · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1209

Elite Clinical Studies LLC

Phoenix · Arizona · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1210

Hero Clinical Research

Phoenix · Arizona · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1211

HonorHealth Research Institute

Scottsdale · Arizona · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1212

Lynn Institute of the Ozarks

Little Rock · Arkansas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1213

University of California San Diego

La Jolla · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1214

InvivoCure

Los Angeles · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1215

Clinical Trials Research - Sacramento

Roseville · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1216

Alliance Clinical Research

San Diego · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1217

Encompass Clinical Research

Spring Valley · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1218

Stanford Health Care

Stanford · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1219

Blue Coast Cardiology

Vista · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1220

Diablo Clinical Research

Walnut Creek · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1221

Focus Clinical Research

West Hills · California · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1222

UCHealth Memorial Central

Colorado Springs · Colorado · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1223

South Denver Cardiology Associates

Littleton · Colorado · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1224

Gandelman Cardiology, PC

Greenwich · Connecticut · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1225

ClinTrial Hamden

Hamden · Connecticut · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1226

Clearwater Cardiovascular Consultants

Clearwater · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1227

Proactive Clinical Research

Fort Lauderdale · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1228

Elite Cardiac Research Center LLC

Hialeah · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
1229

East Coast Institute for Research, LLC

Lake City · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1230

Columbus Clinical Services LLC

Miami · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1231

Kendall South Medical Center

Miami · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1232

Inpatient Research Clinic, LLC

Miami Lakes · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1233

Panax Clinical Research

Miami Lakes · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1234

Indago Research and Health Center

Miami Lakes · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1235

Eminat, LLC

Miramar · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1236

Suncoast Clinical Research Inc

New Port Richey · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1237

Ocala Research Institute, Inc

Ocala · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1238

Ormond Beach Clinical Research

Ormond Beach · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1239

Baptist Health Care

Pensacola · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1240

Denali Health Plant City

Plant City · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1241

FWD Clinical Research

Tamarac · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1242

Clinical Site Partners Orlando dba Flourish Research

Winter Park · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1243

Guardian Research Organization LLC

Winter Park · Florida · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
1244

Emory University Hospital

Atlanta · Georgia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1245

East Coast Institute for Research

Canton · Georgia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1246

Northeast Georgia Medical Center Wisteria Building

Cumming · Georgia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1247

Nsc Research

Johns Creek · Georgia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1248

Georgia Clinical Research

Lawrenceville · Georgia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1249

St Lukes Idaho Cardiology Associates

Meridian · Idaho · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1250

Solaris Clinical Research

Meridian · Idaho · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1251

Endeavor Health-Northwest Community Healthcare

Arlington Heights · Illinois · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1252

Christie Clinic

Champaign · Illinois · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1253

Advocate Lutheran General Hospital

Park Ridge · Illinois · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1254

Alliance for Multispecialty Research LLC - Park Ridge

Park Ridge · Illinois · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1255

MediSphere Medical Research Center LLC

Evansville · Indiana · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1256

Parkview Research Center

Fort Wayne · Indiana · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1257

Franciscan Health Indianapolis

Indianapolis · Indiana · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1258

Ascension Saint Vincent Heart Center

Indianapolis · Indiana · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1259

Cardiovascular Research of Northwest Indiana LLC

Munster · Indiana · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1260

Reid Physician Associates

Richmond · Indiana · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1261

MercyOne Iowa Heart Center

West Des Moines · Iowa · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1262

Hutchinson Clinic PA

Hutchinson · Kansas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1263

University of Kansas Medical Center

Kansas City · Kansas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1264

Midwest Heart and Vascular Specialists

Overland Park · Kansas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1265

Graves Gilbert Clinic

Bowling Green · Kentucky · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1266

Baptist Health Lexington

Lexington · Kentucky · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1267

The Research Group of Lexington LLC

Lexington · Kentucky · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1268

Heart Clinic of Hammond

Covington · Louisiana · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1269

Louisiana Heart Center

Slidell · Louisiana · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1270

Johns Hopkins Hospital

Baltimore · Maryland · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1271

Suburban Hospital

Bethesda · Maryland · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
1272

Flourish Research

Bowie · Maryland · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1273

Medstar Franklin Square Medical Center

Hyattsville · Maryland · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1274

Brigham and Womens Hospital

Boston · Massachusetts · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1275

Henry Ford Health System

Detroit · Michigan · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1276

Healthy Heart Cardiology

Grand Rapids · Michigan · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1277

MyMichigan Medical Center Midland - Clinical Research Department

Midland · Michigan · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1278

Advanced Cardiology Associates

Rochester Hills · Michigan · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1279

Revival Research Institute

Southfield · Michigan · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1280

Saint Marys Medical Center

Duluth · Minnesota · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1281

Health East Cancer Care

Maplewood · Minnesota · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1282

Mayo Clinic

Rochester · Minnesota · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1283

Methodist Hospital

Saint Louis Park · Minnesota · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1284

Jackson Heart Clinic

Jackson · Mississippi · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1285

Cardiology Associates Research LLC

Tupelo · Mississippi · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1286

Sisters of Saint Mary Health Heart and Vascular Care

Bridgeton · Missouri · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1287

Kansas City Veterans Affairs Medical Center

Kansas City · Missouri · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1288

Washington University

St Louis · Missouri · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1289

Bryan Heart

Lincoln · Nebraska · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1290

Physician Research Collaboration, LLC

Lincoln · Nebraska · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1291

Excel Clinical Research

Las Vegas · Nevada · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1292

American Institute of Medical Research

Las Vegas · Nevada · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1293

Las Vegas Clinical Trials

North Las Vegas · Nevada · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1294

Renown Institute for Heart and Vascular Health

Reno · Nevada · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1295

Advanced Heart Care LLC

Bridgewater · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1296

Advanced Heart and Vascular Institute of Hunterdon

Flemington · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1297

Clinical Reseach Philadelphia Pennington

Hamilton · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1298

Med Clinical Research Partners - Irvington

Irvington · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1299

New Jersey Medcare / New Jersey Heart

Linden · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1300

Saint Michaels Medical Center

Newark · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1301

Circuit Clinical / Optum Medical Care of New Jersey

Secaucus · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1302

The Heart House - Washington Township

Sewell · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1303

CardioMetabolic Collaborative Clinic

Somerset · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1304

Ima Clinical Research - Warren

Warren Township · New Jersey · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1305

Basil Clinical

Inwood · New York · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1306

Rasai Research

Jackson Heights · New York · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1307

Crystal Run Healthcare

Monroe · New York · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1308

Mount Sinai Queens

New York · New York · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1309

Niagara Falls Memorial Medical Center

Niagara Falls · New York · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1310

Circuit Clinical Orchard Park Family Practice

Orchard Park · New York · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1311

Hudson Valley Cardiovascular Physicians PC

Poughkeepsie · New York · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1312

Saratoga Clinical Research, LLC

Saratoga Springs · New York · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1313

Duke University Health System

Durham · North Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1314

Moses H Cone Memorial Hospital

Greensboro · North Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1315

Triad Clinical Trials, LLC

Greensboro · North Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1316

ClinCept, LLC

Kinston · North Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1317

Monroe Biomedical Research

Monroe · North Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1318

Piedmont Healthcare

Statesville · North Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1319

Accellacare Research of Wilmington

Wilmington · North Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1320

Wake Forest University Health Sciences

Winston-Salem · North Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1321

Lillestol Research LLC

Fargo · North Dakota · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1322

Aultman Cardiology Clinical Trials

Canton · Ohio · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1323

The Christ Hospital

Cincinnati · Ohio · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1324

Velocity Clinical Research - Cincinnati

Cincinnati · Ohio · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1325

Nexgen Research

Lima · Ohio · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1326

K and R Research

Marion · Ohio · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1327

Alliance for Multispecialty Research

Norman · Oklahoma · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1328

University of Pennsylvania

Philadelphia · Pennsylvania · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1329

Preferred Primary Care Physicians, Inc

Pittsburgh · Pennsylvania · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1330

Pottstown Medical Specialists Inc

Pottstown · Pennsylvania · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1331

Miriam Hospital

East Greenwich · Rhode Island · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1332

Pharmacorp Clinical Trials Inc

Charleston · South Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1333

Prisma Health Carolina Cardiology - Greenville

Gantt · South Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1334

Accellacare Charleston

Mt. Pleasant · South Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1335

Tribe Clinical Research - Spartanburg

Spartanburg · South Carolina · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1336

Erlanger Health, Inc.

Chattanooga · Tennessee · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1337

Apex Research Foundation, LLC

Jackson · Tennessee · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
1338

Alliance for Multispecialty Research Knoxville

Knoxville · Tennessee · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
1339

Ascension Saint Thomas

Nashville · Tennessee · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1340

Parkway Cardiology Associates

Oak Ridge · Tennessee · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1341

Tennessee Center for Clinical Trials

Tullahoma · Tennessee · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1342

PharmaTex Research, LLC

Amarillo · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1343

Texas Diabetes and Endocrinology

Austin · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1344

Ima Clinical Research

Austin · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1345

Pioneer Medical Associates

Carrollton · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1346

Baylor Scott and White Heart and Vascular Hospital-Dallas

Dallas · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1347

The Heartbeat Clinic

Dallas · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1348

Cedar Health Research, LLC

Dallas · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1349

Cedar Health Research, LLC

Euless · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1350

East Texas Cardiology PA

Houston · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1351

Cardiovascular Specialists of Willowbrook

Houston · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1352

Vital Heart and Vein

Humble · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1353

Tcr Institute Llc

Kingwood · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1354

Epic Clinical Research

Lewisville · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1355

Texas Tech University Health Sciences Center

Lubbock · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1356

North Dallas Research Associates

McKinney · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1357

Revival Research Institute

McKinney · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1358

Texas Institute of Cardiology

McKinney · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1359

Southern Endocrinology Associates PA

Mesquite · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1360

Orion Medical

Pasadena · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1361

Valley Institute of Research Plano

Plano · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1362

St Davids Heart & Vascular PLLC dba Austin Heart

San Marcos · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1363

Tyler Cardiovascular Consultants

Tyler · Texas · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1364

Alpine Research Organization

Layton · Utah · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1365

Inova Cardiology - Fairfax

Fairfax · Virginia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1366

Virginia Heart - Loudoun

Leesburg · Virginia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1367

Bon Secours Cardiology

Midlothian · Virginia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1368

Tidewater Physicians Multispecialty Group Clinical Research

Newport News · Virginia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1369

Alliance for Multispecialty Research Norfolk

Norfolk · Virginia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1370

Centricity Research

Suffolk · Virginia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1371

Selma Medical Associates

Winchester · Virginia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1372

Winchester Medical Center

Winchester · Virginia · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
1373

Western Washington Medical Group

Everett · Washington · United States

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1374

Canberra Hospital

Garran · Australian Capital Territory · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1375

Royal Prince Alfred Hospital

Camperdown · New South Wales · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1376

Novatrials

Charlestown · New South Wales · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1377

Concord Repatriation General Hospital

Concord · New South Wales · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1378

Orange Health Service

Orange · New South Wales · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1379

Wollongong Hospital

Wollongong · New South Wales · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1380

Advara HeartCare Wesley

Auchenflower · Queensland · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1381

Core Research Group Pty Ltd

Milton · Queensland · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1382

University of The Sunshine Coast Clinical Trials, Sippy Downs

Sippy Downs · Queensland · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1383

Dr Heart Pty Ltd

Woolloongabba · Queensland · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1384

Flinders Medical Centre

Bedford Park · South Australia · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1385

The Alfred Hospital

Melbourne · Victoria · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1386

Momentum Clinical Research - Sunshine

Melbourne · Victoria · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1387

Clinitrials - Mandurah

Greenfields · Western Australia · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1388

Hollywood Private Hospital

Nedlands · Western Australia · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1389

Linear Clinical Research Limited

Nedlands · Western Australia · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1390

Clinitrials - West Perth

Perth · Western Australia · Australia

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1391

Centricity Research Calgary

Calgary · Alberta · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1392

Edmonton Cardiology Consultants

Edmonton · Alberta · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1393

Fraser Clinical Trials

New Westminster · British Columbia · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1394

SMH Cardiology Clinical Trials Incorporated

Surrey · British Columbia · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1395

ARC Biosystems Incorporated

Vancouver · British Columbia · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1396

Discovery Clinical Services Ltd

Victoria · British Columbia · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1397

Centricity Research Brampton

Brampton · Ontario · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1398

Cambridge Cardiac Care Centre

Cambridge · Ontario · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1399

Elevate Clinical Research KMH Missisauga

Mississauga · Ontario · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1400

Partners in Advanced Cardiac Evaluation

Newmarket · Ontario · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1401

Oakville Cardiovascular Research

Oakville · Ontario · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1402

Heart Health Institute Research Incorporated

Scarborough Village · Ontario · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1403

Montreal Heart Institute

Montreal · Quebec · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1404

Institut de recherches cliniques de Montreal

Montreal · Quebec · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1405

Centre de Recherche du Centre Hospitalier de l Universite de Montreal

Montreal · Quebec · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1406

Research Institute of McGill University Health Center - Glen Site

Montreal · Quebec · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1407

CIUSSS de l Estrie CHUS Hopital Fleurimont

Sherbrooke · Quebec · Canada

1 trial
Olpasiran prevents first heart attack or stroke in people at risk with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
1408

Alliance for Multispecialty Research, LLC

Daphne · Alabama · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1409

SEC Clinical Research

Dothan · Alabama · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1410

Alliance for Multispecialty Research, LLC

Mobile · Alabama · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1411

Sun City Clinical Research

Glendale · Arizona · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1412

Elite Clinical Studies, LLC

Phoenix · Arizona · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1413

Helios Clinical Research - Phoenix

Phoenix · Arizona · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1414

Absolute Clinical Research

Phoenix · Arizona · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1415

Synexus Clinical Research US, Inc./Orange Grove Family Practice

Tucson · Arizona · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1416

Cardiology and Medicine Clinic

Little Rock · Arkansas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1417

Valley Clinical Trials, Inc.

Covina · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1418

HB Clinical Trials - Fountain Valley

Fountain Valley · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1419

Scripps Whittier Diabetes Institute

La Jolla · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1420

First Valley Medical Group

Lancaster · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1421

MemorialCare Health System - Long Beach Medical Center

Long Beach · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1422

Ark Clinical Research

Long Beach · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1423

Keck School of Medicine of USC

Los Angeles · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1424

Cardiovascular Research Foundation of Southern California

Los Angeles · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1425

Desert Oasis Healthcare Medical Group

Palm Springs · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1426

Artemis Institute for Clinical Research

San Diego · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1427

Care Access - Santa Clarita

Santa Clarita · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1428

Stanford University Medical Center

Stanford · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1429

Olive View-UCLA Medical Center

Sylmar · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1430

Care Access - Thousand Oaks

Thousand Oaks · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1431

Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.

Toluca Lake · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1432

InvivoCure

Van Nuys · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1433

Synexus Clinical Research US, Inc.

Vista · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1434

Millennium Clinical Trials

Westlake Village · California · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1435

CMR of Greater New Haven, LLC

Hamden · Connecticut · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1436

Hartford Hospital (HH)

Hartford · Connecticut · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1437

MedStar Washington Hospital Center

Washington D.C. · District of Columbia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1438

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Clearwater · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1439

Clinical Research of West Florida, Inc. (Clearwater)

Clearwater · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1440

Elite Cardiac Research Center

Hialeah · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1441

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Largo · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1442

South Florida Clinical Research Institute

Margate · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1443

Flourish Research - Miami, LLC

Miami · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1444

CTR Oakwater, LLC

Orlando · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1445

Florida Institute For Clinical Research, LLC

Orlando · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1446

Innovative Research Institute - Port Charlotte

Port Charlotte · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1447

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Safety Harbor · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1448

Clinical Research of West Florida

Tampa · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1449

Cardiology Partners Clinical Research Institute - Wellington

Wellington · Florida · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1450

American Clinical Trials - Acworth

Acworth · Georgia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1451

Atlanta Diabetes Associates

Atlanta · Georgia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1452

Emory University School of Medicine

Atlanta · Georgia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1453

East Coast Institute for Research - Canton

Canton · Georgia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1454

American Clinical Trials - Douglasville

Douglasville · Georgia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1455

Georgia Clinical Research - Lawrenceville

Lawrenceville · Georgia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1456

The Jones Center Clinical Research

Macon · Georgia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1457

CARE Institute

Meridian · Idaho · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1458

Chicago Clinical Research Institute

Chicago · Illinois · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1459

Clinical Investigation Specialists

Gurnee · Illinois · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1460

Alliance for Multispecialty Research, LLC

Niles · Illinois · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1461

Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative

Springfield · Illinois · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1462

Accellacare - DuPage

Winfield · Illinois · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1463

American Health Network of Indiana, LLC - Avon

Avon · Indiana · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1464

American Health Network of Indiana, LLC - Franklin

Franklin · Indiana · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1465

Care Access - South Indianapolis

Indianapolis · Indiana · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1466

Iowa Diabetes and Endocrinology Research Center

West Des Moines · Iowa · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1467

Cotton O'Neil Clinical Research Center

Topeka · Kansas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1468

AMR Clinical

Wichita · Kansas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1469

Qualmedica Research

Bowling Green · Kentucky · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1470

Alliance for Multispecialty Research, LLC

Lexington · Kentucky · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1471

Grace Research - Bossier

Bossier City · Louisiana · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1472

Care Access - Lake Charles

Lake Charles · Louisiana · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1473

Alliance for Multispecialty Research, LLC

New Orleans · Louisiana · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1474

Louisiana Heart Center - Slidell

Slidell · Louisiana · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1475

Sinai Hospital Of Baltimore

Baltimore · Maryland · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1476

Care Access - Baltimore

Baltimore · Maryland · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1477

MedStar Good Samaritan Hospital

Baltimore · Maryland · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1478

Jadestone Clinical Research

Beltsville · Maryland · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1479

Kur Research - Columbia Medical

Columbia · Maryland · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1480

MedStar Health Research Institute (MedStar Physician Based Research Network)

Hyattsville · Maryland · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1481

NECCR PrimaCare Research

Fall River · Massachusetts · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1482

Alliance for Multispecialty Research, LLC.

Dearborn · Michigan · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1483

Michigan Heart & Vascular Institute

Ypsilanti · Michigan · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1484

Memorial Hospital at Gulfport

Diamondhead · Mississippi · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1485

Clinvest Headlands Llc

Springfield · Missouri · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1486

Las Vegas Endocrinology

Henderson · Nevada · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1487

DaVita Clinical Research - Las Vegas

Las Vegas · Nevada · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1488

Palm Research Center Tenaya

Las Vegas · Nevada · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1489

Internal Medicine Associates

Bridgeton · New Jersey · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1490

Atlantic Health System Overlook Medical Center

Summit · New Jersey · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1491

IMA Clinical Research Warren

Warren Township · New Jersey · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1492

Albany Medical College, Division of Community Endocrinology

Albany · New York · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1493

St. Francis Hospital & Heart Center

New Hyde Park · New York · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1494

NYU Langone Health

New York · New York · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1495

University of Rochester Medical Center

Rochester · New York · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1496

Saratoga Clinical Research

Saratoga Springs · New York · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1497

Stony Brook University

Stony Brook · New York · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1498

Triad Clinical Trials

Greensboro · North Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1499

Physician's East Endocrinology

Greenville · North Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1500

IMA Clinical Research Mount Airy

Mount Airy · North Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1501

Accellacare - Raleigh

Raleigh · North Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1502

Accellacare - Wilmington

Wilmington · North Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1503

Wake Forest Baptist Health

Winston-Salem · North Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1504

Velocity Clinical Research, Cleveland

Beachwood · Ohio · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1505

Velocity Clinical Research, Mt. Auburn

Cincinnati · Ohio · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1506

Velocity Clinical Research, Springdale

Cincinnati · Ohio · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1507

Cleveland Clinic

Cleveland · Ohio · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1508

Centricity Research Columbus Ohio Multispecialty

Columbus · Ohio · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1509

Good Samaritan Regional Medical Center

Corvallis · Oregon · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1510

Heritage Valley Multispecialty Group, Inc

Beaver · Pennsylvania · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1511

Abington Medical Specialists

Horsham · Pennsylvania · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1512

Lancaster General Hospital

Lancaster · Pennsylvania · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1513

AHN Allegheny General Hospital

Pittsburgh · Pennsylvania · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1514

Preferred Primary Care Physicians

Uniontown · Pennsylvania · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1515

Cardiology Consultants of Philadelphia Yardley

Yardley · Pennsylvania · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1516

Accellacare Trident Cardiology

Charleston · South Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1517

Tribe Clinical Research, LLC

Greenville · South Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1518

Care Access - Mauldin

Mauldin · South Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1519

Accellacare - Mt Pleasant

Mt. Pleasant · South Carolina · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1520

Monument Health Rapid City Hospital

Rapid City · South Dakota · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1521

Alliance for Multispecialty Research, LLC

Knoxville · Tennessee · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1522

Care Access - Memphis 2

Memphis · Tennessee · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1523

Amarillo Heart Clinical Research Institute Inc.

Amarillo · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1524

IMA Clinical Research Austin

Austin · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1525

Velocity Clinical Research, Austin

Austin · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1526

Headlands Horizons LLC

Brownsville · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1527

South Texas Clinical Research

Corpus Christi · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1528

Private Practice - Dr. James E. Race

Dallas · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1529

Baylor Soltero CV Research Center

Dallas · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1530

Cedar Health Research

Dallas · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1531

Cardio Voyage

Denison · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1532

South Texas Research Institute

Edinburg · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1533

Juno Research

Houston · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1534

Biopharma Informatic, LLC

Houston · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1535

PlanIt Research, PLLC

Houston · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1536

Accurate Clinical Research - Humble

Humble · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1537

The Heart Institute of East Texas

Lufkin · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1538

Wellness Clinical Research

McKinney · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1539

North Texas Research Associates

McKinney · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1540

Texas Institute of Cardiology, PA

McKinney · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1541

Southern Endocrinology Associates

Mesquite · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1542

Clinical Advancement Center

San Antonio · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1543

Clinical Trials of Texas, LLC

San Antonio · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1544

Endeavor Clinical Trials

San Antonio · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1545

Consano Clinical Research, LLC

Shavano Park · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1546

DaVita Clinical Research - North Houston

Shenandoah · Texas · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1547

Alpine Research Organization

Clinton · Utah · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1548

Alliance for Multispecialty Research, LLC

Norfolk · Virginia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1549

IMA Clinical Research West Virginia

Morgantown · West Virginia · United States

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1550

Clínica Privada del Prado SRL

Alberdi · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1551

Fundación favaloro para la Docencia e Investigación Médica

Buenos Aires · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1552

CEDIC

CABA · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1553

Sanatorio Privado Duarte Quirós

Córdoba · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1554

CIDIM-Centro Integral de Diagnostico por Imagenes Marchegiani

Córdoba · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1555

MICA - Medicina e Investigación Cardiometabólica

Del Viso · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1556

Hospital Italiano de La Plata

La Plata · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1557

Clínica Privada Independencia

Munro · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1558

Centro Privado de Medicina Respiratoria

Paraná · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1559

CER medical Institute

Quilmes · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1560

Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica

Rosario · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1561

Centro Cardiovascular Salta

Salta · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1562

Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L

San Miguel de Tucumán · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1563

Go Centro Medico San Nicolás

San Nicolás · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1564

Clínica de Nefrología, Urología y Enfermedades Cardiovasculares

Santa Fe · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1565

Sanatorio San Martin

Venado Tuerto · Argentina

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1566

Advara HeartCare Leabrook

Adelaide · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1567

Paratus Clinical Research Western Sydney

Blacktown · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1568

Emeritus Research

Botany · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1569

Cholesterol Care

Brisbane · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1570

Paratus Clinical Research Canberra

Bruce · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1571

Emeritus Research

Camberwell · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1572

Austin Health - Repatriation Hospital

Heidelberg West · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1573

Paratus Clinical Research Brisbane

Herston · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1574

Paratus Clinical Research Central Coast

Kanwal · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1575

Liverpool Hospital

Liverpool · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1576

Logan Hospital

Meadowbrook · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1577

AusTrials - Sunshine

Melbourne · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1578

University of the Sunshine Coast (UniSC) Clinical Trials - Noosa

Noosaville · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1579

Royal Perth Hospital

Perth · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1580

Momentum St. Leonards

Sydney · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1581

Townsville University Hospital

Townsville · Australia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1582

Medizinische Universitaet Innsbruck

Innsbruck · Austria

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1583

Université Libre de Bruxelles - Hôpital Erasme

Brussels · Belgium

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1584

Grand Hôpital de Charleroi

Charleroi · Belgium

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1585

AZ Sint-Blasius

Dendermonde · Belgium

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1586

AZ Maria Middelares

Ghent · Belgium

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1587

UZ Gent

Ghent · Belgium

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1588

Jessa Ziekenhuis

Hasselt · Belgium

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1589

Instituto Aramari Apo

Asa Norte · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1590

Santa Casa de Misericordia de Belo Horizonte

Belo Horizonte · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1591

Freire Pesquisa Clínica

Belo Horizonte · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1592

L2IP - Instituto de Pesquisas Clínicas

Brasília · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1593

Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Brasília

Brasília · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1594

PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR

Curitiba · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1595

Nucleo De Pesquisa Clinica

Curitiba · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1596

Centro de Pesquisas Clínicas Dr. Marco Mota

Maceió · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1597

CHN - Complexo Hospitalar de Niterói

Niterói · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1598

Hospital São Lucas da PUCRS

Porto Alegre · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1599

CAPED Centro Avancado Pesquisa e Diagnostica

Ribeirão Preto · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1600

Instituto D'Or Pesquisa e Ensino

Rio de Janeiro · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1601

Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador

Salvador · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1602

Hospital Ana Nery (HAN) - Salvador

Salvador · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1603

Hospital Da Bahia

Salvador · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1604

Faculdade de Medicina do ABC

Santo André · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1605

Centro Multidisciplinar de Estudos Clinicos

São Bernardo do Campo · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1606

BP - A Beneficencia Portuguesa de São Paulo

São Paulo · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1607

Hospital Alemao Oswaldo Cruz

São Paulo · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1608

Hospital do Coracao

São Paulo · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1609

IBCC - Núcleo de Pesquisa e Ensino

São Paulo · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1610

Instituto de Molestias Cardiovasculares de Tatui

Tatuí · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1611

Eurolatino Pesquisas Medicas

Uberlândia · Brazil

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1612

Cardio Health Clinical Trial - Brampton

Brampton · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1613

Milestone Research Inc.

London · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1614

Cardio Health Clinical Trial - London

London · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1615

Fraser Clinical Trials Inc

New Westminster · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1616

The Medical Arts Health Research Group

North Vancouver · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1617

Oakville Cardiovascular Research LP

Oakville · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1618

Medical Arts Health Research Group

Penticton · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1619

Clinique des Maladies Lipidiques de Québec

Québec · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1620

ALPHA Recherche Clinique

Québec · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1621

Unité de Recherche Clinique du CISSS des Laurentides

Saint-Jérôme · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1622

Cardio Health Clinical Trial - St. Thomas

St. Thomas · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1623

SMH Cardiology Clinical Trials

Surrey · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1624

Care Access - Cape Breton

Sydney · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1625

Centre de Medecine Metabolique de Lanaudiere (CMML)

Terrebonne · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1626

Corcare

Toronto · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1627

Diabetes Heart Research Centre

Toronto · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1628

ARC Biosystems

Vancouver · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1629

Winnipeg Clinic

Winnipeg · Canada

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1630

Beijing Chaoyang Hospital, Capital Medical University

Beijing · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1631

Beijing Friendship Hospital Affiliate of Capital University

Beijing · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1632

The Third Xiangya Hospital of Central South University

Changsha · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1633

Changzhou Second People's Hospital

Changzhou · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1634

Chifeng Hospital

Chifeng · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1635

Dalian Municipal Central Hospital Affiliated of Dalian Medical University

Dalian · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1636

Shunde Hospital of Southern Medical Univesity

Foshan · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1637

Guangzhou First People's Hospital

Guangzhou · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1638

The Fourth Affiliated Hospital of Harbin Medical University

Harbin · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1639

Inner Mongolia People's Hospital

Hohhot · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1640

Huizhou Municipal Central Hospital

Huizhou · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1641

Jingzhou Central Hospital

Jingzhou · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1642

The First Hospital of Lanzhou University

Lanzhou · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1643

The Second Affiliated Hospital of Nanchang University

Nanchang · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1644

The Third Hospital of Nanchang

Nanchang · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1645

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Nanjing · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1646

The Second Affiliated Hospital of Nanjing Medical University

Nanjing · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1647

Guangxi People's Hospital

Nanning · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1648

Nanyang Second General Hospital

Nanyang · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1649

The First Affiliated Hospital of Nanyang Medical College

Nanyang · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1650

Ningbo First Hospital

Ningbo · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1651

Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1652

Shanghai Putuo District Center Hospital

Shanghai · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1653

Shanghai East Hospital

Shanghai · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1654

Shanghai No. 6 People's Hospital - Jinshan Central Hospital

Shanghai · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1655

The People's Hospital of Liaoning Province

Shenyang · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1656

Shenzhen Sun Yat-sen Cardiovascular Hospital

Shenzhen · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1657

The First Affiliated Hospital of Soochow University

Suzhou · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1658

Tianjin Fourth Centre Hospital

Tianjin · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1659

TEDA International Cardiovascular Hospital

Tianjin · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1660

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1661

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1662

Wuhan University Medical College - Hubei Zhongshan Hospital

Wuhan · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1663

Wuhan Asia Heart Hospital

Wuhan · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1664

Wuxi People's Hospital

Wuxi · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1665

Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army

Xi'an · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1666

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1667

Xiamen Cardiovascular Hospital

Xiamen · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1668

General Hospital of Ningxia Medical University

Yinchuan · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1669

The First People's Hospital of Yueyang

Yueyang · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1670

The Second Affiliated Hospital of Zhengzhou University

Zhengzhou · China

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1671

MEDICUS SERVICES s.r.o., kardiologicka ambulance

Brandýs nad Labem · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1672

Vojenská Nemocnice Brno

Brno · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1673

Kardiologicka ambulance

Litovel · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1674

EDUMED - Náchod

Náchod · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1675

Agentura Science Pro

Olomouc · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1676

PreventaMed

Olomouc · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1677

Kardiologicka a Angiologicka Ambulance

Ostrava · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1678

Private Practice - Dr. Miroslav Koliba

Ostrava · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1679

Kardio Uhrineves

Prague · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1680

Synexus Czech

Prague · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1681

Nefrologie

Prague · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1682

Centrum Kardiovaskularni Mediciny

Prague · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1683

Nova kardiologie - Kardiologicka ambulance

Říčany · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1684

Kardiologicka ambulance MUDr. Ferkl s.r.o.

Trutnov · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1685

Clinical Trials Service s.r.o.

Uherské Hradiště · Czechia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1686

Sygehus Sønderjylland i Aabenraa

Aabenraa · Denmark

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1687

Aarhus Universitetshospital, Skejby

Aarhus · Denmark

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1688

Rigshospitalet

Copenhagen · Denmark

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1689

Esbjerg sygehus, Syddansk Universitetshospital

Esbjerg · Denmark

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1690

Herlev and Gentofte Hospital

Herlev · Denmark

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1691

Holbæk Sygehus

Holbæk · Denmark

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1692

Hôpital Avicenne

Bobigny · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1693

Hospices Civils de Lyon - Hopital Louis Pradel

Bron · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1694

CHRU Troussau

Chambray-lès-Tours · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1695

Centre Hospitalier Compiègne-Noyon

Compiègne · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1696

Centre Hospitalier Louis Pasteur

Le Coudray · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1697

Hôpital de la Conception

Marseille · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1698

Hôpital Saint Joseph

Marseille · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1699

CHU Montpellier Lapeyronie Hospital

Montpellier · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1700

Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau

Nîmes · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1701

Centre Hospitalier de Pau

Pau · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1702

CHU Bordeaux Haut-Leveque

Pessac · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1703

Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou

Rennes · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1704

CHU Charles Nicolle

Rouen · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1705

Polyclinique Vauban

Valenciennes · France

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1706

Klinikum am Plattenwald

Bad Friedrichshall · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1707

Praxis Rankestrasse

Berlin · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1708

DRK Kliniken Berlin - Köpenick

Berlin · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1709

Klinikum Bielefeld Mitte

Bielefeld · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1710

Universitaetsklinikum Koeln

Cologne · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1711

Medizentrum Essen Borbeck

Essen · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1712

BAG Diabeteszentrum Dr. Tews & Partner

Gelnhausen · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1713

Universitätsklinikum Jena

Jena · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1714

Universitätsmedizin Mannheim

Mannheim · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1715

Kardiologische Gemeinschaftspraxis am Park Sanssouci

Potsdam · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1716

Universitaet zu Koeln - Sana-Klinikum Remscheid GmbH - Klinik fuer Kardiologie, Pneumologie und Internisti -T

Remscheid · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1717

GPR Gesundheits- und Pflegezentrum Rüsselsheim

Rüsselsheim am Main · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1718

Zentrum für klinische Studien

Saint Ingbert · Germany

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1719

Athens Naval Hospital

Athens · Greece

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1720

General Hospital of Athens Laiko

Athens · Greece

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1721

Athens Medical Center

Athens · Greece

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1722

Attikon General University Hospital

Chaïdári · Greece

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1723

Iatriko Paleou Falirou Medical Center

Palaió Fáliro · Greece

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1724

Papageorgiou General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1725

DRC Gyógyszervizsgáló Központ

Balatongyörök · Hungary

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1726

Privát Doktor Egészségügyi Zrt

Budapest · Hungary

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1727

Eszak-Pesti Centrumkorhaz-Honvedkorhaz

Budapest · Hungary

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1728

Debreceni Egyetem Klinikai Kozpont

Debrecen · Hungary

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1729

Sardar Patel Medical College

Bikaner · India

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1730

Shri Mahant Indiresh Hospital

Dehradun · India

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1731

Lisie Hospital

Kochi · India

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1732

Emek Medical Center

Afula · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1733

Soroka Medical Center

Beersheba · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1734

Rambam Health Care Campus

Haifa · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1735

Carmel Hospital

Haifa · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1736

Linn Medical Center

Haifa · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1737

Edith Wolfson Medical Center

Holon · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1738

Shaare Zedek Medical Center

Jerusalem · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1739

Hadassah Medical Center

Jerusalem · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1740

Meir Medical Center

Kfar Saba · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1741

Galilee Medical Center

Nahariya · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1742

Rabin Medical Center

Petah Tikva · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1743

Sheba Medical Center

Ramat Gan · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1744

Kaplan Medical Center

Rehovot · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1745

Clalit Health Services - Sakhnin Community Clinic

Sakhnin · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1746

Sourasky Medical Center

Tel Aviv · Israel

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1747

Ospedale Bassini

Cinisello Balsamo · Italy

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1748

AOU Policlinico Umberto I

Rome · Italy

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1749

Asahi Hospital - Asahi

Asahi · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1750

Asahikawa City Hospital

Asahikawa · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1751

Saiseikai Futsukaichi Hospital

Chikushino-shi · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1752

University of Yamanashi Hospital

Chūō · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1753

Tokyo-Eki Center-building Clinic

Chūōku · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1754

Fukuwa Clinic

Chūōku · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1755

Fukuoka Wajiro Hospital

Fukuoka · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1756

Public Matto Ishikawa Central Hospital

Hakusan · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1757

Hyogo Prefectural Harima-Himeji General Medical Center

Himeji · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1758

Tokai University Hospital

Isehara · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1759

Rinku General Medical Center

Izumisano · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1760

Takai Internal Medicine Clinic

Kamakura-shi · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1761

Ishikawa Prefectural Central Hospital

Kanazawa · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1762

National Hospital Organization Kanazawa Medical Center

Kanazawa · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1763

Kasugai Municipal Hospital

Kasugai · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1764

Kokura Memorial Hospital

Kitakyushu · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1765

Kobe City Medical Center General Hospital

Kobe · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1766

Komatsu Municipal Hospital

Komatsu · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1767

Jinnouchi Hospital

Kumamoto · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1768

Kurashiki Central Hospital

Kurashiki · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1769

Chugoku Rosai Hospital

Kure · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1770

Rakuwakai Marutamachi Hospital

Kyoto · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1771

Rakuwakai Otowa Hospital

Kyoto · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1772

Aizawa Hospital

Matsumoto · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1773

National Hospital Organization Tokyo Medical Center

Meguro-ku · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1774

Tokyo Saiseikai Central Hospital

Minatoku · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1775

Miyakonojo Medical Association Hospital - Tarobocho

Miyakonojō · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1776

Kanazawa Medical University Hospital

Mukai-awagasaki · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1777

Tachikawa Medical Center

Nagaoka · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1778

Shonan Oiso Hospital

Naka-gun · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1779

Nogata Clinic

Nakano · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1780

Okayama City General Medical Center Okayama City Hospital

Okayama · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1781

National Hospital Organization Okayama Medical Center

Okayama · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1782

Medical Corporation Sato Medical clinic

Ootaku · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1783

National Hospital Organization - Osaka National Hospital - Institute For Clinical Research

Osaka · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1784

Kansai Electric Power Hospital

Osaka · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1785

Osaki Citizen Hospital - Furukawahonami

Ōsaki · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1786

Saga University Hospital

Saga · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1787

Kitasato University Hospital

Sagamihara · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1788

Sanai Hospital - Saitama

Saitama · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1789

Tokeidai Memorial Hospital

Sapporo · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1790

Heishinkai Medical Group ToCROM Clinic

Shinjuku-ku · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1791

National Center for Global Health and Medicine

Shinjyuku-ku · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1792

Medical Corporation Heishinkai OCROM Clinic

Suita-shi · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1793

Shizuoka Medical Center

Sunto-gun · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1794

Higashi Takarazuka Satoh Hospital

Takarazuka · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1795

Takasago Seibu Hospital

Takasago · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1796

National Hospital Organization Shinshu Ueda Medical Center

Ueda · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1797

Saiseikai Yokohamashi Tobu Hospital

Yokohama · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1798

Yokosukakyosai

Yokosuka · Japan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1799

Centro de Investigación Cardiometabólica de Aguascalientes

Aguascalientes · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1800

Hospital Cardiologica Aguescalientes

Aguascalientes · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1801

Enclifar Ensayos Clínicos Farmacológicos Sc

Chihuahua City · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1802

Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia

Durango · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1803

Diseno y Planeacion en Investigacion Medica

Guadalajara · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1804

Centro de Investigacion Medica Integral

Guadalajara · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1805

CINVEC Medica

Guadalajara · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1806

Investigación Médica Sonora, S.C.

Hermosillo · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1807

RM Pharma Specialists

Mexico City · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1808

Clínicos Asociados BOCM

Mexico City · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1809

Clinica Omega

Mexico City · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1810

Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares

Mexico City · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1811

ProcliniQ Investigación Clínica SA de CV

Mexico City · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1812

Clinstile, S.A. de C.V.

México · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1813

Christus - Latam Hub Center of Excellence and Innovation S.C.

Monterrey · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1814

Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

Monterrey · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1815

Clinica de Enfermedades Crónicas y de Procedimientos Especiales

Morelia · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1816

Centro de Estudios Clínicos de Querétaro (CECLIQ)

Querétaro · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1817

PanAmerican Clinical Research - Querétaro - Avenida Antea

Querétaro · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1818

Centro de Investigacion Cardiovascular y Metabólica

Tijuana · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1819

Instituto Veracruzano en Investigación Clínica S.C.

Veracruz · Mexico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1820

Gelre Ziekenhuis

Apeldoorn · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1821

Rode Kruis Ziekenhuis

Beverwijk · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1822

Reinier de Graaf Ziekenhuis, locatie Delft

Delft · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1823

Deventer Ziekenhuis

Deventer · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1824

Slingeland Ziekenhuis

Doetinchem · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1825

Catharina Ziekenhuis

Eindhoven · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1826

Admiraal de Ruyter Ziekenhuis, locatie Goes

Goes · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1827

Groene Hart Ziekenhuis

Gouda · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1828

General Practitioners Research Institute (GPRI)

Groningen · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1829

Martini Ziekenhuis

Groningen · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1830

Spaarne Gasthuis, Haarlem Zuid

Haarlem · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1831

Saxenburgh Medisch Centrum

Hardenberg · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1832

Medische Centrum Leeuwarden

Leeuwarden · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1833

Ikazia Ziekenhuis

Rotterdam · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1834

Antonius Ziekenhuis, locatie D&A Research and Genetics

Sneek · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1835

Haga Ziekenhuis locatie Leyweg

The Hague · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1836

ETZ TweeSteden

Tilburg · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1837

Zaans Medisch Centrum

Zaandam · Netherlands

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1838

Specderm Poznanska sp.j.

Bialystok · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1839

NZOZ Centrum Medyczne KERmed

Bydgoszcz · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1840

Centrum Medyczne INTERCOR Sp. z o.o.

Bydgoszcz · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1841

Polsko-Amerykańskie Kliniki Serca PAKS Małopolskie Centrum Sercowo-Naczyniowe

Chrzanów · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1842

Polsko-Amerykańskie Kliniki Serca

Dąbrowa Górnicza · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1843

Centrum Kliniczno-Badawcze

Elblag · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1844

Uniwersyteckie Centrum Kliniczne

Gdansk · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1845

Przychodnie Grudziądz

Grudziądz · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1846

Polsko-Amerykańskie Kliniki Serca

Kędzierzyn-Koźle · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1847

Pro Salus Centrum Medyczne

Lodz · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1848

1 Wojskowy Szpital Kliniczny w Lublinie

Lublin · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1849

CenterMed Lublin NZOZ

Lublin · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1850

Wielospecjalistyczny Szpital Samodzielny Publiczny Zakład Opieki Zdrowotnej w Nowej Soli

Nowa Sól · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1851

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu

Przemyśl · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1852

AKA-MED Centrum

Ruda Śląska · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1853

Polsko-Amerykańskie Kliniki Serca

Tychy · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1854

Clinical Best Solutions

Warsaw · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1855

Balsam Medica

Warsaw · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1856

Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś

Warsaw · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1857

NZOZ Centurm Medyczne SERAFIN-MED

Żarów · Poland

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1858

GCM Medical Group, PSC - Hato Rey Site

San Juan · Puerto Rico

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1859

CMI Cardiologie - Dr. Mercea Corina Delia

Baia Mare · Romania

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1860

CMI DNBM Dr. Pop Lavinia

Baia Mare · Romania

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1861

C.M.D.T.A. Neomed

Brasov · Romania

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1862

Centrul Medical Endocrinologie si Diabet Dr. Paveliu

Bucharest · Romania

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1863

Spitalul Clinic Județean de Urgență

Craiova · Romania

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1864

Centrul Medical Consultmed

Iași · Romania

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1865

Cardiomed Iași

Iași · Romania

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1866

Cardiomed

Târgu Mureş · Romania

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1867

Cliniq s.r.o.

Bratislava · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1868

ENDIAMED s.r.o

Dolný Kubín · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1869

JM-Interna s.r.o

Dolný Kubín · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1870

IN-DIA

Lučenec · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1871

NEDÚ - Národný endokrinologický a diabetologický ústav n.o.

Ľubochňa · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1872

Sin Azucar

Malacky · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1873

AMBORA s.r.o. Interna ambulancia

Martin · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1874

Fakultná nemocnica Nitra

Nitra · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1875

MEDIKALS

Piešťany · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1876

MEDISPOL

Prešov · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1877

ENRIN, s.r.o.

Rimavská Sobota · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1878

Tatratrial s.r.o.

Rožňava · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1879

Areteus s.r.o.

Trebišov · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1880

MediPrax, s.r.o.

Trstená · Slovakia

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1881

The Catholic University of Korea, Bucheon St. Mary's Hospital

Bucheon-si · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1882

Keimyung University Dongsan Hospital

Daegu · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1883

Eulji University Hospital

Daejeon · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1884

Boramae Medical Center

Dongjak-gu · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1885

Chonnam National University Hospital

Gwangju · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1886

Kyung Hee University Hospital

Seoul · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1887

Seoul National University Hospital

Seoul · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1888

Kyung Hee University Hospital at Gangdong

Seoul · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1889

Sejong General Hospital

Sosa-gu · South Korea

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1890

Hospital Universitario Fundacion ALcorcon

Alcorcón · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1891

Hospital Germans Trias i Pujol

Badalona · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1892

Hospital de la Santa Creu i Sant Pau

Barcelona · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1893

Hospital de Denia Marina Salud

Denia · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1894

Hospital Clínico Universitario Virgen de la Arrixaca

El Palmar, Murcia · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1895

Hospital de Cabueñes

Gijón · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1896

Hospital Universitari de Girona Doctor Josep Trueta

Girona · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1897

Hospital Lucus Augusti

Lugo · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1898

Hospital Universitario La Paz

Madrid · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1899

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1900

Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1901

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca

Salamanca · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1902

Hospital de Sant Joan Despí Moisès Broggi

Sant Joan Despí · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1903

Hospital Arnau de Vilanova

Valencia · Spain

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1904

Changhua Christian Hospital

Changhua County · Taiwan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1905

Fu Jen Catholic University Hospital

New Taipei City · Taiwan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1906

Chung Shan Medical University Hospital

Taichung · Taiwan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1907

National Cheng Kung University Hospital

Tainan · Taiwan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1908

National Yang Ming Chiao Tung University Hospital

Yilan · Taiwan

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1909

Panthera Biopartners - Glasgow

Glasgow · United Kingdom

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1910

Hull Royal Infirmary

Hull · United Kingdom

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1911

Royal Free Hospital

London · United Kingdom

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1912

Royal Victoria Infirmary

Newcastle upon Tyne · United Kingdom

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1913

Salford Royal Hospital

Salford · United Kingdom

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1914

Torbay Hospital

Torquay · United Kingdom

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1915

Sunderland Royal Hospital

Tyne and Wear · United Kingdom

1 trial
Lepodisiran reduces heart attack and stroke risk in adults with high lipoprotein(a).
Eli Lilly and CompanyPh 3NCT06292013 ↗
1916

Jacksonville Center for Clinical

Jacksonville · Florida · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1917

K2 Medical Research LLC

Maitland · Florida · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗
1918

University of Miami Hospital

Miami · Florida · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1919

Baptist Health South

Miami · Florida · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1920

FXM Clin Res Miramar LLC

Miramar · Florida · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1921

University Of South Florida

Tampa · Florida · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1922

FC Site Partners Miami

Winter Park · Florida · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1923

American Health Network Research Dept

Muncie · Indiana · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1924

Flourish Research Bowie

Bowie · Maryland · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1925

Aa Mrc Llc

Flint · Michigan · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1926

MyMichigan Medical Center Midland

Midland · Michigan · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1927

The Corvallis Clinic P C

Corvallis · Oregon · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1928

Novartis Investigative Site

Tullahoma · Tennessee · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1929

PharmaTex Research LLC

Amarillo · Texas · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1930

Kelsey Seybold Research Foundation

Houston · Texas · United States

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1931

Novartis Investigative Site

Yinchuan · Ningxia · China

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗
1932

Novartis Investigative Site

Béziers · France

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1933

Novartis Investigative Site

Cholet · France

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1934

Novartis Investigative Site

Montpellier · France

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1935

Novartis Investigative Site

Stuttgart · Baden-Wurttemberg · Germany

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1936

Novartis Investigative Site

Singen · Germany

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1937

Novartis Investigative Site

Grosseto · GR · Italy

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1938

Novartis Investigative Site

Legnago · VR · Italy

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1939

Latin Clinical Trial Center Inc

San Juan · Puerto Rico

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1940

Novartis Investigative Site

Pamplona · Navarre · Spain

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1941

Novartis Investigative Site

Castilleja de la Cuesta · Sevilla · Spain

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1942

Novartis Investigative Site

Las Palmas GC · Spain

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1943

Novartis Investigative Site

Changhua · Taiwan

1 trial
Pelacarsen reduces lipoprotein(a) levels in heart disease patients already taking inclisiran for high cholesterol.
Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗
1944

National Institutes of Health Clinical Center

Bethesda · Maryland · United States

1 trial
Human milk oligosaccharide supplement restores healthy gut bacteria balance in people with microbiome imbalance.
National Heart, Lung, and Blood Institute (NHLBI)Ph 1 (early)RecruitingNCT06615986 ↗
1945

Site Number - 1056

Huntsville · Alabama · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1946

Site Number - 1041

Mobile · Alabama · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1947

Site Number - 1017

Phoenix · Arizona · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1948

Site Number - 1025

Scottsdale · Arizona · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1949

Site Number - 1042

Tucson · Arizona · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1950

Site Number - 1010

Carlsbad · California · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1951

Site Number - 1028

Irvine · California · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1952

Site Number - 1023

Los Angeles · California · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1953

Site Number - 1029

Rancho Mirage · California · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1954

Site Number - 1004

San Francisco · California · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1955

Site Number - 1027

Fort Collins · Colorado · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1956

Site Number - 1001

New Haven · Connecticut · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1957

Site Number - 1024

Washington D.C. · District of Columbia · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1958

Site Number - 1006

Clearwater · Florida · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1959

Site Number - 1037

Ormond Beach · Florida · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1960

Site Number - 1002

Port Charlotte · Florida · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1961

Site Number - 1050

Rockledge · Florida · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1962

Site Number - 1007

Tampa · Florida · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1963

Site Number - 1014

Atlanta · Georgia · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1964

Site Number - 1043

Augusta · Georgia · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1965

Site Number - 1054

Schaumburg · Illinois · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1966

Site Number - 1022

Lexington · Kentucky · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1967

Site Number - 1032

Nicholasville · Kentucky · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1968

Site Number - 1046

New Orleans · Louisiana · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1969

Site Number - 1049

Foxborough · Massachusetts · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1970

Site Number - 1026

Detroit · Michigan · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1971

Site Number - 1005

East Lansing · Michigan · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1972

Site Number - 1018

Omaha · Nebraska · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1973

Site Number - 1019

Totowa · New Jersey · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1974

Site Number - 1036

New York · New York · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1975

Site Number - 1034

New York · New York · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1976

Site Number - 1020

Chapel Hill · North Carolina · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1977

Site Number - 1013

Durham · North Carolina · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1978

Site Number - 1044

Raleigh · North Carolina · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1979

Site Number - 1038

Cincinnati · Ohio · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1980

Site Number - 1045

Oklahoma City · Oklahoma · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1981

Site Number - 1011

Yukon · Oklahoma · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1982

Site Number - 1031

Eugene · Oregon · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1983

Site Number - 1030

Charleston · South Carolina · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1984

Site Number - 1015

Charleston · South Carolina · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1985

Site Number - 1021

Memphis · Tennessee · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1986

Site Number - 1003

Dallas · Texas · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1987

Site Number - 1047

Denton · Texas · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1988

Site Number - 1048

Lubbock · Texas · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1989

Site Number - 1009

Charlottesville · Virginia · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1990

Site Number - 1040

Richmond · Virginia · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1991

Site Number - 1035

Greenfield · Wisconsin · United States

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1992

Site Number - 5002

Rosario · Argentina

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1993

Site Number - 3201

Brno · Czechia

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1994

Site Number - 3601

Copenhagen · Denmark

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1995

Site Number - 8002

Tbilisi · Georgia

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1996

Site Number - 8003

Tbilisi · Georgia

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1997

Site Number - 8001

Tbilisi · Georgia

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1998

Site Number - 6502

Bochum · Germany

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
1999

Site Number - 6504

Goettigen · Germany

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2000

Site Number - 6505

Magdeburg · Germany

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2001

Site Number - 6503

Würzburg · Germany

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2002

Site Number - 3903

Athens · Greece

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2003

Site Number - 3902

Athens · Greece

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2004

Site Number - 3901

Pátrai · Greece

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2005

Site Number - 3904

Thessaloniki · Greece

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2006

Site Number - 7552

Budapest · Hungary

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2007

Site Number - 7553

Budapest · Hungary

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2008

Site Number - 7551

Kistarcsa · Hungary

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2009

Site Number - 6003

Bergamo · Italy

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2010

Site Number - 6002

Milan · Italy

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2011

Site Number - 6001

Naples · Italy

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2012

Site Number - 6004

Rome · Italy

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2013

Site Number - 3005

Gdansk · Poland

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2014

Site Number - 3001

Katowice · Poland

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2015

Site Number - 3006

Krakow · Poland

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2016

Site Number - 3002

Krakow · Poland

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2017

Site Number - 3003

Krakow · Poland

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2018

Site Number - 3004

Lublin · Poland

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2019

Site Number - 3007

Warsaw · Poland

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2020

Site Number - 7502

Constanța · Romania

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2021

Site Number - 7501

Târgu Mureş · Romania

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2022

Site Number - 9001

Belgrade · Serbia

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2023

Site Number - 9002

Niš · Serbia

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2024

Site Number - 7103

Barcelona · Spain

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2025

Site Number - 7101

Córdoba · Spain

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2026

Site Number - 7104

Madrid · Spain

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2027

Site Number - 7002

Glasgow · United Kingdom

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2028

Site Number - 7004

London · United Kingdom

1 trial
IMVT-1402 treats muscle weakness in adults with generalized myasthenia gravis.
Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗
2029

Precision Clinical Research

Sunrise · Florida · United States

1 trial
Weekly alirocumab injections lower cholesterol in adults with high blood cholesterol levels.
Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗
2030

Balanced Life Health Care Solutions

Lawrenceville · Georgia · United States

1 trial
Weekly alirocumab injections lower cholesterol in adults with high blood cholesterol levels.
Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗
2031

Velocity Clinical Research - Durham

Durham · North Carolina · United States

1 trial
Weekly alirocumab injections lower cholesterol in adults with high blood cholesterol levels.
Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗
2032

Velocity Clinical Research, Medford

Medford · Oregon · United States

1 trial
Weekly alirocumab injections lower cholesterol in adults with high blood cholesterol levels.
Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗
2033

Velocity Clinical Research Dallas

Dallas · Texas · United States

1 trial
Weekly alirocumab injections lower cholesterol in adults with high blood cholesterol levels.
Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗
2034

Valley Clinical Trials Inc

Covina · California · United States

1 trial
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
2035

Tulane Center for Clinical Research

New Orleans · Louisiana · United States

1 trial
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
2036

Novartis Investigative Site

Buenos Aires · Argentina

1 trial
Long-term pelacarsen treatment safety study for participants completing prior cholesterol-lowering trials.
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
2037

Alliance Clinical

Canoga Park · California · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2038

Zenith Clinical Research

Hollywood · Florida · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2039

Atlanta Heart Specialists LLC

Tucker · Georgia · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2040

AMR Chicago

Niles · Illinois · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2041

CV Ins of the South

Lafayette · Louisiana · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2042

Trinity Health Michigan Heart

Ypsilanti · Michigan · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2043

Cardiology Associates of North MS

Tupelo · Mississippi · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2044

K and R Research LLC

Marion · Ohio · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2045

TCV Clinical Studies

Linwood · Pennsylvania · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2046

Alliance for Multispecialty Research

Knoxville · Tennessee · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2047

Angiocardiac Care of Texas PA

Houston · Texas · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2048

Dallas Heart and Vascular Consultants PA

Houston · Texas · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2049

Biopharma Informatic

Katy · Texas · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2050

Clinical Trials of Texas

San Antonio · Texas · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2051

MultiCare Ins Research Innovation

Puyallup · Washington · United States

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2052

Novartis Investigative Site

Luoyang · Henan · China

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2053

Novartis Investigative Site

Gladbeck · Germany

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2054

Novartis Investigative Site

Papenburg · Germany

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2055

Novartis Investigative Site

Rostock · Germany

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2056

Novartis Investigative Site

Suita · Osaka · Japan

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2057

Novartis Investigative Site

Shinjuku Ku · Tokyo · Japan

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2RecruitingNCT07235046 ↗
2058

Novartis Investigative Site

Kyoto · Japan

1 trial
DII235 lowers lipoprotein(a) levels in adults with elevated cardiovascular risk factor.
Novartis PharmaceuticalsPh 2ActiveNCT07235046 ↗
2059

Research Site

Aramil · Russia

1 trial
Laroprovstat combined with rosuvastatin reduces LDL cholesterol in Russian adults with high cholesterol.
AstraZenecaPh 2NCT07218900 ↗
2060

Research Site

Ivanovo · Russia

1 trial
Laroprovstat combined with rosuvastatin reduces LDL cholesterol in Russian adults with high cholesterol.
AstraZenecaPh 2NCT07218900 ↗
2061

Research Site

Moscow · Russia

1 trial
Laroprovstat combined with rosuvastatin reduces LDL cholesterol in Russian adults with high cholesterol.
AstraZenecaPh 2NCT07218900 ↗
2062

Research Site

Perm · Russia

1 trial
Laroprovstat combined with rosuvastatin reduces LDL cholesterol in Russian adults with high cholesterol.
AstraZenecaPh 2NCT07218900 ↗
2063

Research Site

Saint Petersburg · Russia

1 trial
Laroprovstat combined with rosuvastatin reduces LDL cholesterol in Russian adults with high cholesterol.
AstraZenecaPh 2NCT07218900 ↗
2064

Research Site

Inverness · Florida · United States

1 trial
AZD4954 safety and effectiveness study in healthy adults and those with high cholesterol or lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
2065

Research Site

Jacksonville · Florida · United States

1 trial
AZD4954 safety and effectiveness study in healthy adults and those with high cholesterol or lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
2066

Research Site

Port Orange · Florida · United States

1 trial
AZD4954 safety and effectiveness study in healthy adults and those with high cholesterol or lipoprotein(a).
AstraZenecaPh 1Opening soonNCT06980428 ↗
2067

Research Site

Brooklyn · Maryland · United States

1 trial
AZD4954 safety and effectiveness study in healthy adults and those with high cholesterol or lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
2068

Research Site

San Antonio · Texas · United States

1 trial
AZD4954 safety and effectiveness study in healthy adults and those with high cholesterol or lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
2069

Axsendo Clinical Research - Peak Heart & Vascular - Phoenix

Phoenix · Arizona · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2070

Southwest Kidney Institute - Surprise

Surprise · Arizona · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2071

John Muir Medical Center - Concord Campus

Concord · California · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2072

Ark Clinical Research - Fountain Valley

Fountain Valley · California · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2073

The Cardiovascular Center

Redding · California · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2074

Legacy Clinical Trials

Colorado Springs · Colorado · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2075

OptumCare Clinical Trials, LLC

Golden · Colorado · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3CompletedNCT07157774 ↗
2076

FWD Clinical Research

Boca Raton · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2077

American Research Institute

Cutler Bay · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2078

K2 Medical Research - Daytona Beach

Daytona Beach · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2079

Arrow Clinical Trials

Daytona Beach · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2080

Soffer Health Institute

Hollywood · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2081

K2 MEDICAL Research THE VILLAGES

Lady Lake · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2082

K2 Medical Research ORLANDO

Maitland · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2083

Dade Florida Clinical Research Center

Miami · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2084

Onhealth Research Center

Miami · Florida · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2085

Masters of Clinical Research

Augusta · Georgia · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2086

Elite Clinical Trials

Blackfoot · Idaho · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2087

Elite Clinical Trials

Rexburg · Idaho · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2088

AMR Clinical

Niles · Illinois · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2089

IU Health Bloomington

Bloomington · Indiana · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2090

Tulane University School of Medicine

New Orleans · Louisiana · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2091

MaineHealth Cardiology

Scarborough · Maine · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2092

Metropolitan Cardiovascular Consultants

Beltsville · Maryland · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2093

Lucida Clinical Trials

New Bedford · Massachusetts · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2094

Boeson Research MSO

Missoula · Montana · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2095

Clinical Research of South Nevada

Las Vegas · Nevada · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2096

Vector Clinical Trials

Sparks · Nevada · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2097

Clinical Research of Philadelphia

Pennington · New Jersey · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2098

Southwest Cardiovascular Center

Albuquerque · New Mexico · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2099

NYC Research

New York · New York · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2100

Weill Cornell Medical College

New York · New York · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2101

Rochester Clinical Research, LLC

Rochester · New York · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2102

SUNY Upstate Medical University

Syracuse · New York · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2103

Southgate Medical Group

West Seneca · New York · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2104

Kaiser Permanente Sunnyside Medical Center

Clackamas · Oregon · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2105

Advanced Research Institute - Tigard

Tigard · Oregon · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2106

Altoona Center For Clinical Research

Duncansville · Pennsylvania · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2107

M3 Wake Research - Charleston

Charleston · South Carolina · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2108

Circle Clinical Research

Sioux Falls · South Dakota · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2109

WR-Clinsearch, LLC

Chattanooga · Tennessee · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2110

The Jackson Clinic

Jackson · Tennessee · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2111

St. David's Heart & Vascular PLLC dba Austin Heart

Austin · Texas · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2112

Dallas VA Medical Center

Dallas · Texas · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2113

Southwest Family Medicine Associates

Dallas · Texas · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2114

Renal Disease Research Institute

Dallas · Texas · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2115

IntraCare

Dallas · Texas · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2116

Cedar Health Research - Fort Worth

Fort Worth · Texas · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2117

GMG Clinical Research (DBA Radiance Clinical Research) - Lampasas

Lampasas · Texas · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2118

ERA Health Research-Texas

Midland · Texas · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2119

Ogden Clinic - Canyon View

Ogden · Utah · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2120

Advanced Research Institute

Ogden · Utah · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2121

Mary Washington Hospital

Fredericksburg · Virginia · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2122

Carient Heart & Vascular - Manassas

Manassas · Virginia · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2123

Manassas Clinical Research Center

Manassas · Virginia · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2124

TPMG (Tidewater Physicians Multispecialty Group) Clinical Research

Newport News · Virginia · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2125

Dominion Medical Associates, Inc.

Richmond · Virginia · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2126

ERA Health Research - CardioNow - Lynnwood

Lynnwood · Washington · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2127

Universal Research Group

Tacoma · Washington · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2128

Central Washington Health Services Association d/b/a Confluence Health

Wenatchee · Washington · United States

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2129

CEC - Consultorios de Especialidades Cardiovasculares

Bahía Blanca · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2130

CONEXA Investigacion Clinica S.A.

Buenos Aires · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2131

Kynet

Buenos Aires · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2132

Cicemo Srl

Buenos Aires · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2133

Cardiología Palermo

Buenos Aires · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2134

Mautalen Salud e Investigación

Buenos Aires · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2135

CEMEDIAB

C.a.b.a. · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2136

Centro Medico Privado San Vicente Diabetes

Córdoba · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2137

CMD-Centro Médico y Diagnóstico por Imágenes

Junín · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2138

Polo de Salud Vistalba

Lujan de Cuyo · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2139

Fundacion Scherbovsky

Mendoza · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2140

Centro Rosarino de Investigaciones Clinicas (CRICs)

Rosario · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2141

Santa Maria de la Salud Centro Medico

San Isidro · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2142

Centro de Salud e Investigaciones Médicas

Santa Rosa · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2143

Centro de Investigaciones Medicas Temperley

Temperley · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2144

Instituto de Investigaciones Clinicas Zarate

Zárate · Argentina

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2145

Royal Hobart Hospital

Hobart · Australia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2146

Ipswich Hospital

Ipswich · Australia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2147

Sydney Cardiometabolic Centre

Liverpool · Australia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2148

Maroochy Private Hospital

Maroochydore · Australia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2149

Advara HeartCare - Milton

Milton · Australia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2150

Southern Adelaide Diabetes & Endocrine Services

Oaklands Park · Australia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2151

Latrobe Regional Health

Traralgon · Australia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2152

Medizinische Universität Graz

Graz · Austria

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2153

Cardio Metabolic Centre

Mattersburg · Austria

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2154

imed St. Pölten

Sankt Pölten · Austria

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2155

Imed19-privat

Vienna · Austria

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2156

AZORG Campus Aalst-Moorselbaan

Aalst · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2157

ANIMA Research

Alken · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2158

AZ Sint-Jan Brugge-Oostende AV

Bruges · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2159

Jan Yperman Ziekenhuis

Ieper · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2160

Kormont

Kluisbergen · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2161

Clinical Chc Montlégia

Liège · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2162

InoKura

Liège · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2163

Gezondheidshuis De Gloed

Machelen · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2164

Meclinas

Mechelen · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2165

Pneumocare

Namur · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2166

Artsen Netwerk De Schelde

Oudenaarde · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2167

Artsenpraktijk OHIO

Oudenaarde · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2168

Private Practice - Dr. De Watertoren

Tielt · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2169

Private Practice - Dr. Tim Decraecke (Zwalm)

Zwalm · Belgium

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2170

Hospital Sirio Libanes

Brasília · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2171

Hospital do Coração do Brasil

Brasília · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2172

Instituto de Ensino e Pesquisa Clinica do Ceara

Fortaleza · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2173

C-MEP - Centro Multidisciplinar de Ensino e Pesquisa

Joinville · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2174

CPHOSP Manaus Medicina, Ensino e Pesquisa

Manaus · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2175

Instituto Atena de Pesquisa Clinica

Natal · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2176

Hospital Maternidade E Pronto Socorro Santa Lucia

Poços de Caldas · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2177

Irmandade da Santa Casa de Misericórdia de Porto Alegre

Porto Alegre · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2178

Rede AME SAÚDE

Recife · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2179

Centro de Pesquisa Silvestre Santé

Rio Branco · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2180

Inovace Pesquisa Clínica

Salvador · Brazil

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2181

Winterberry Research Inc.

Hamilton · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2182

Institut de Cardiologie de Montreal

Montreal · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2183

IUCPQ

Québec · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2184

Bluewater Clinical Research Group Inc.

Sarnia · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2185

KMH Cardiology Centres - Stoney Creek

Stoney Creek · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2186

Unity Health Toronto, St. Michael's Hospital

Toronto · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2187

Riverside Cardiology and Diagnostic Imaging

Toronto · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2188

Fadia El Boreky Medicine

Waterloo · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2189

Clinical Research Solutions - Kitchener

Waterloo · Canada

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2190

Peking University First Hospital

Beijing · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2191

Xuanwu Hospital Capital Medical University

Beijing · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2192

Beijing Pinggu District Hospital

Beijing · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2193

Xiangya Hospital Central South University

Changsha · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2194

The First People's Hospital of Changzhou

Changzhou · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2195

Daqing People's Hospital

Daqing · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2196

The First People's Hospital of Foshan

Foshan · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2197

Zhujiang Hospital

Guangzhou · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2198

Zhejiang Hospital

Hangzhou · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2199

Jining No.1 People's Hospital

Jining · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2200

Huaihe Hospital of Henan University

Kaifeng · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2201

The First Affiliated Hospital of Henan University of Science &Technology

Luoyang Shi · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2202

Affiliated Hospital of Luzhou Medical College

Luzhou · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2203

Nanchang People's Hospital

Nanchang · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2204

Jiangxi Provincial People's Hospital

Nanchang · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2205

Zhongda Hospital Southeast University

Nanjing · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2206

Jiangsu Province Hospital

Nanjing · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2207

The first affiliated hospital of Ningbo university

Ningbo · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2208

Shanghai Xuhui Central Hospital

Shanghai · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2209

The First Affiliated Hospital of Shantou University Medical College

Shantou · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2210

The Second Affiliated Hospital of Soochow University

Suzhou · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2211

The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Wenzhou · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2212

Xuzhou Central Hospital

Xuzhou · China

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2213

Kardiologie Stříbrný

Brno · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2214

MUDr. Karel Kamenik - Kardiologicka Ambulance

Brno · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2215

Kardio Chlumec

Chlumec nad Cidlinou · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2216

INTENDIA klinika s.r.o.

Chrudim III · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2217

DR. HAUS - Kardiologicka Ambulance

Český Krumlov · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2218

DIKa Centrum

Havířov · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2219

CTC Hodonin s.r.o.

Hodonín · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2220

Fakultni nemocnice Hradec Kralove

Hradec Králové · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2221

Cévní ambulance Nový Jičín

Nový Jičín · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2222

MUDr. Buchta s.r.o., Kardiologicka ambulance

Ostrava · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2223

Pratia Pardubice a.s.

Pardubice · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2224

Diabet2 s.r.o., diabetologicka a interni ambulance

Prague · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2225

Clinoxus

Prague · Czechia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2226

Centre Hospitalier d'Annecy

Epagny Metz-Tessy · France

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2227

Chu Grenoble Alpes

La Tronche · France

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2228

Centre Hospitalier Universitaire de Poitiers

Poitiers · France

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2229

Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord

Saint-Priest-en-Jarez · France

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2230

Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau

Tours · France

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2231

Klinische Forschung Berlin-Mitte

Berlin · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2232

FutureMeds GmbH

Berlin · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2233

Klinische Forschung Dresden

Dresden · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2234

Zentrum für klinische Prüfungen in der Facharztzentrum Dresden-Neustadt Betriebsgesellschaft mbH

Dresden · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2235

Unterfrintroper Hausarztzentrum Klinische Forschung

Essen · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2236

ClinPhenomics CVC GmbH

Frankfurt · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2237

Universitaetsklinikum Freiburg

Freiburg im Breisgau · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2238

Nephrologisches Zentrum Göttingen

Göttingen · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2239

Universitätsmedizin Greifswald

Greifswald · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2240

HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg GmbH / -T

Hamburg · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2241

Velocity Clinical Research, Hamburg

Hamburg · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2242

Klinische Forschung Hamburg

Hamburg · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2243

Klinische Forschung Hannover-Mitte

Hanover · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2244

Klinische Forschung Karlsruhe

Karlsruhe · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2245

Universität zu Lübeck - Institut für Endokrinologie und Diabetes

Lübeck · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2246

Dedicated Research Site FutureMeds

Offenbach · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2247

RED-Institut GmbH

Oldenburg · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2248

Klinische forschung Schwerin GmbH

Schwerin · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2249

Evangelisches Krankenhaus Witten

Witten · Germany

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2250

Evangelismos General Hospital of Athens

Athens · Greece

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2251

Athens Medical Center - Psychikon branch

Athens · Greece

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2252

General Hospital of Nikaia-Piraeus "Agios Panteleimon"

Nikaia Piraeus · Greece

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2253

University Hospital of Patras

Pátrai · Greece

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2254

G. Gennimatas General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2255

Euromedica General Clinic of Thessaloniki

Thessaloniki · Greece

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2256

Ippokrateio General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2257

European Interbalkan Medical Center

Thessaloniki · Greece

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2258

Semmelweis Egyetem

Budapest · Hungary

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2259

Gottsegen György Országos Kardiovaszkuláris Intézet

Budapest · Hungary

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2260

Cardiogeneral Egészségügyi Kft.

Budapest · Hungary

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2261

Arina Trial Research

Orosháza · Hungary

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2262

CoroMed

Pécs · Hungary

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2263

KomplexLabor Diagnosztika

Szeged · Hungary

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2264

Belagavi Institute of Medical Sciences - Belagavi

Belgavi · India

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2265

Eternal Heart Care Center and Research Institute

Jaipur · India

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2266

Sanjay Gandhi Post Graduate Institute of Medical Sciences

Lucknow · India

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2267

Kingsway Hospitals (Best Multispeciality Hospital in Nagpur)

Nagpur · India

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2268

Sir Ganga Ram Hospital

New Delhi · India

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2269

Ashirwad Hospital and Research Centre

Ulhasnagar · India

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2270

Azienda Ospedaliera di Caserta Sant' Anna e San Sebastiano

Caserta · Italy

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2271

Azienda Ospedaliero Universitaria S.Anna

Ferrara (Cona) · Italy

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2272

A.O.U. Policlinico Paolo Giaccone

Palermo · Italy

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2273

Fondazione IRCCS Policlinico San Matteo

Pavia · Italy

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2274

Azienda Ospedaliera Sant'Andrea

Rome · Italy

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2275

Akita University Hospital

Akita · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2276

Yamasaki Family Clinic

Amagasaki · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2277

Institute of Science Tokyo Hospital

Bunkyō · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2278

Shonan Fujisawa Tokushukai Hospital

Fujisawa · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2279

Tenjin Sogo Clinic

Fukuoka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2280

Hamanomachi Hospital

Fukuoka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2281

Fukuoka University Hospital

Fukuoka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2282

Kyushu Central Hospital

Fukuoka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2283

Gifu University Hospital

Gifu · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2284

Hachioji Diabetes Clinic

Hachioji-shi · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2285

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

Hiroshima · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2286

Hiroshima Prefectural Hospital

Hiroshima · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2287

National Kohnodai Medical Center

Ichikawa · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2288

Nippon Medical School Chiba Hokusoh Hospital

Inzai · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2289

Nihon University Itabashi Hospital

Itabashiku · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2290

Shimane University Hospital

Izumo · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2291

Shonan Kamakura General Hospital

Kamakura · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2292

Mizonokuchi Okamoto Clinic

Kawasaki · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2293

Teikyo University Mizonokuchi Hospital

Kawasaki · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2294

Kobe University Hospital

Kobe · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2295

Yoshimura Clinic

Kumamoto · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2296

Omi Medical Center

Kusatsu · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2297

Toho University Ohashi Medical Center

Meguro-ku · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2298

Yokoi Clinic

Minoh · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2299

Nakamoto Internal Medicine Clinic

Mito · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2300

MinamiAkatsukaClinic

Mito · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2301

Nagasaki Harbor Medical Center

Nagasaki · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2302

Japan Public Health Association

Nagoya · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2303

Nakakinen clinic

Naka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2304

Nishiyamadou Keiwa Hospital

Naka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2305

International University of Health and Welfare Narita Hospital

Narita · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2306

Shimamura Memorial Hospital

Nerima-ku · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2307

Okayama Rosai Hospital

Okayama · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2308

Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai

Osaka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2309

Osaka Metropolitan University Hospital

Osaka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2310

Minamiosaka Hospital

Osaka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2311

Abe Clinic

Ōita · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2312

Sato Hospital - Osaki

Ōsaki · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2313

Toho University Omori Medical Center

Ōta-ku · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2314

Medical Corporation Koshinkai - Thyroid and Diabetes Clinic Nakanoshima

Sapporo · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2315

Cardiovascular Hospital Of Central Japan - Kitakanto Cardiovascular Hospital

Shibukawa · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2316

Clinical Research Hospital Tokyo

Shinjuku-ku · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2317

Tokyo Asbo Clinic

Tokyo · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2318

Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic

Yamato-shi · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2319

SHOWA Medical University Fujigaoka Hospital

Yokohama · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2320

Yokohama Minami Kyosai Hospital

Yokohama · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2321

Yokosuka City General Medical Center

Yokosuka · Japan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2322

Centro de Atencion al Diabetico Actopan

Actopan · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2323

Medical Center Metas

Chihuahua City · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2324

Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.

Ciudad Madero · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2325

Centro de Investigación Clínica y Medicina Traslacional (CIMeT)

Guadalajara · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2326

Diseno y Planeacion en Investigacion Medica - Guadalajara - Calle Amado Nervo

Guadalajara · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2327

Instituto Jalisciense de Metabolismo

Guadalajara · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2328

Private Practice - Dr. Arechavaleta Granell Maria del Rosario

Guadalajara · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2329

Salud Cardiovascular

Guadalajara · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2330

Hermosillo Heart Team - Sinacor Hermosillo

Hermosillo · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2331

Accelerium Clinical Research

Mazatlán · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2332

Centro Médico Lic. Arturo Montiel Rojas ISSEMYM

Metepec · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2333

Centro de Investigacion en Artritis y Osteoporosis SC

Mexicali · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2334

RM Pharma Specialists - Unidad Especializada en Datos

Mexico City · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2335

Centro de Investigación Clinica Chapultepec

Mexico City · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2336

Private Practice - Dr. Eduardo Julián José Roberto Chuquiure Valenzuela

Mexico City · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2337

Instituto Nacional de Cardiologia Ignacio Chavez

Mexico City · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2338

Centro de Desarrollo Biomedico

Mérida · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2339

Kohler & Milstein Research S.A. De C.V.

Mérida · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2340

Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares

México · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2341

CEINV Salud

Monterrey · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2342

IMED Internal Medicine Clin Trials

Monterrey · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2343

Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC

Morelia · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2344

Centro Medico Zambrano Hellion

San Pedro Garza García · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2345

Fundación Santos y de la Garza Evía I.B.P

San Pedro Garza García · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2346

Scientia Investigación Clínica TJ

Tijuana · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2347

Arké SMO S.A de C.V

Veracruz · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2348

FAICIC S. de R.L. de C.V.

Veracruz · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2349

Integradora Multidisciplinaria Del Grijalva - Sinacor Villahermosa

Villahermosa · Mexico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2350

Noordwest Ziekenhuisgroep

Alkmaar · Netherlands

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2351

EB Medical Research

Almere Stad · Netherlands

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2352

OLVG Oost

Amsterdam · Netherlands

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2353

Ziekenhuis Rijnstate

Arnhem · Netherlands

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2354

PT&R / PreCare Trial & Recruitment

Born · Netherlands

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2355

Ziekenhuis Bethesda

Hoogeveen · Netherlands

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2356

Canisius-Wilhelmina Ziekenhuis

Nijmegen · Netherlands

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
2357

Albert Schweitzer Ziekenhuis, locatie Zwijndrecht

Zwijndrecht · Netherlands

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2358

Pro&Diagnostic

Bielsko-Biala · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2359

Centrum Medyczne "Hipokrates" S.C. Elżbieta I Grzegorz Grześk

Bydgoszcz · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2360

Euromedica

Grudziądz · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2361

Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero

Katowice · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2362

Centrum Medyczne Komorniki

Komorniki · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2363

FutureMeds - Lodz

Lodz · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2364

Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie

Lublin · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2365

IRMED

Piotrkow Trybunalski · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2366

Futuremeds Targowek

Warsaw · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2367

Przychodnia FutureMeds Wrocław

Wroclaw · Poland

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2368

Investigadores del Este

Humacao · Puerto Rico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2369

Research and Cardiovascular Corp.

Ponce · Puerto Rico

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2370

Cardioplus Center SRL

Baia Mare · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2371

Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu

Baloteşti · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2372

Centrul Medical Unirea

Brasov · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2373

Delta Health Care

Bucharest · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2374

The National Institute of Diabetes, Nutrition and Metabolic Diseases "Prof. Dr. N. Paulescu"

Bucharest · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2375

Spitalul Clinic Profesor Doctor Theodor Burghele

Bucharest · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2376

Diabet Med

Bucharest · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2377

Medical Practice SRL

Oradea · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2378

Spital Clinic Judetean de Urgenta Tg.Mures

Tg.Mures · Romania

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2379

PreMedix

Bratislava · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2380

Ambulancia diabetológie a porúch látkovej premeny a výživy - DIABEDA

Bratislava · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2381

Narodny ustav srdcovych a cievnych chorob

Bratislava · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2382

Nemocnica s poliklinikou Dunajska Streda, a.s.

Dunajská Streda · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2383

Nemocnica s poliklinikou Sv. Lukasa Galanta, a. s.

Galanta · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2384

Cardio D&R

Košice · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2385

MediVet s.r.o.

Malacky · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2386

Nemocnica Malacky

Malacky · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2387

Nemocnica s poliklinikou Stefana Kukuru Michalovce a.s.

Michalovce · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2388

BENIMED s.r.o. Kardiologicka ambulancia

Piešťany · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2389

Vseobecna nemocnica Rimavska Sobota

Rimavská Sobota · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2390

Nemocnica s poliklinikou Spišská Nová Ves

Spišská Nová Ves · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2391

Vranovska Nemocnica

Vranov nad Topľou · Slovakia

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2392

Chosun University Hospital

Gwangju · South Korea

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2393

Hospital San Rafael - La Coruña

A Coruña · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2394

Hospital Universitari Vall d'Hebron

Barcelona · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2395

EAP Osona Sud - Alt Congost S.L.P

Centelles · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2396

Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2397

Complejo Asistencial Universitario de León - Hospital de León

León · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2398

Complejo Hospitalario Ruber Juan Bravo

Madrid · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2399

Hospital La Princesa

Madrid · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2400

Hospital Universitario Infanta Leonor

Madrid · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2401

Hospital Quirón Málaga

Málaga · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2402

H.R.U Málaga - Hospital General

Málaga · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2403

CHOP - Hospital Universitario Montecelo

Pontevedra · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2404

Centro de Salud San Juan de la Cruz

Pozuelo de Alarcón · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2405

Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)

Seville · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2406

Hospital Quiron Infanta Luisa

Seville · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2407

Hospital Universitario de Toledo

Toledo · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2408

Hospital Vithas Valencia 9 de octubre

Valencia · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2409

Hospital Universitario Rio Hortega

Valladolid · Spain

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2410

National Cheng-Kung Uni. Hosp.

Tainan · Taiwan

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2411

South Eastern Health and Social Care Trust

Belfast · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2412

Glan Clwyd Hospital

Bodelwyddan · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2413

Bradford on Avon Health Centre

Bradford-on-Avon · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2414

FutureMeds Glasgow - CPS Research

Glasgow · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2415

Velocity Clinical Research, High Wycombe

High Wycombe · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2416

HMC Health Group - Meadows Centre for Health

Hounslow · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2417

Raigmore Hospital

Inverness · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2418

Oak Tree Surgery

Liskeard · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2419

FutureMeds - London

London · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2420

The Adam Practice

Poole · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2421

Rame Group Practice

Torpoint · United Kingdom

1 trial
Muvalaplin reduces heart attack and stroke risk in people with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2422

Novartis Investigative Site

Hefei · Anhui · China

1 trial
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
2423

Novartis Investigative Site

Fuzhou · Fujian · China

1 trial
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
2424

Novartis Investigative Site

Shenzhen · Guangdong · China

1 trial
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
2425

Novartis Investigative Site

Zunyi · Guizhou · China

1 trial
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
2426

Novartis Investigative Site

Wuhan · Hubei · China

1 trial
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
2427

Novartis Investigative Site

Nanchang · Jiangxi · China

1 trial
Inclisiran reduces coronary plaque buildup in heart attack patients with high cholesterol, measured by imaging.
Novartis PharmaceuticalsPh 4RecruitingNCT06372925 ↗
2428

UC San Francisco Medical Center

San Francisco · California · United States

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2429

Nova Clinical Research LLC

Bradenton · Florida · United States

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2430

Midwest Heart and Vascular Spec

Overland Park · Kansas · United States

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2431

Tufts Medical Center

Boston · Massachusetts · United States

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2432

William Beaumont Hospital

Royal Oak · Michigan · United States

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2433

New York Presbyterian Hospital

New York · New York · United States

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2ActiveNCT05646381 ↗
2434

Orion Medical

Houston · Texas · United States

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2435

Novartis Investigative Site

Yvoir · Namur · Belgium

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2436

Novartis Investigative Site

Roeselare · West-Vlaanderen · Belgium

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2437

Novartis Investigative Site

Cambridge · Ontario · Canada

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2438

Novartis Investigative Site

North York · Ontario · Canada

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2439

Novartis Investigative Site

Ottawa · Ontario · Canada

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2440

Novartis Investigative Site

Hradec Králové · Czechia

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2441

Novartis Investigative Site

Jaroměř · Czechia

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2442

Novartis Investigative Site

Hvidovre · Denmark

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2443

Novartis Investigative Site

Rennes · France

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2444

Novartis Investigative Site

Ahaus · Germany

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2445

Novartis Investigative Site

Bonn · Germany

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2446

Novartis Investigative Site

Oldenburg · Germany

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2447

Novartis Investigative Site

Nahariya · Israel

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2448

Novartis Investigative Site

Tel Aviv · Israel

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2449

Novartis Investigative Site

Padova · PD · Italy

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2450

Novartis Investigative Site

Rotterdam · South Holland · Netherlands

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2451

Novartis Investigative Site

Nieuwegein · Utrecht · Netherlands

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2452

Novartis Investigative Site

Alcabideche · Portugal

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2453

Novartis Investigative Site

Braga · Portugal

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2454

Novartis Investigative Site

Vila Nova de Gaia · Portugal

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2455

Novartis Investigative Site

Lugano · Switzerland

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2456

Novartis Investigative Site

Reading · Berkshire · United Kingdom

1 trial
Pelacarsen injections slow aortic valve hardening in patients with elevated lipoprotein(a) levels.
Novartis PharmaceuticalsPh 2RecruitingNCT05646381 ↗
2457

Novartis Investigative Site

Anqing · Anhui · China

1 trial
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
2458

Novartis Investigative Site

Chongqing · Chongqing Municipality · China

1 trial
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
2459

Novartis Investigative Site

Longyan · Fujian · China

1 trial
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
2460

Novartis Investigative Site

Jiamusi · Heilongjiang · China

1 trial
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
2461

Novartis Investigative Site

Weifang · Shandong · China

1 trial
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
2462

Novartis Investigated Site

Taiyuan · Shanxi · China

1 trial
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
2463

Novartis Investigative Site

Jinhua · Zhejiang · China

1 trial
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗
2464

Novartis Investigative Site

Ningbo · Zhejiang · China

1 trial
Inclisiran effectively lowers cholesterol in Chinese heart disease patients compared to standard care.
Novartis PharmaceuticalsPh 4NCT06941792 ↗